U.S. patent application number 10/164290 was filed with the patent office on 2004-06-10 for compositions and methods for evaluating viral receptor/co-receptor usage and inhibitors of virus entry using recombinant virus assays.
Invention is credited to Huang, Wei, Parkin, Neil T., Petropoulos, Christos J., Whitcomb, Jeannette.
Application Number | 20040110125 10/164290 |
Document ID | / |
Family ID | 32474015 |
Filed Date | 2004-06-10 |
United States Patent
Application |
20040110125 |
Kind Code |
A1 |
Petropoulos, Christos J. ;
et al. |
June 10, 2004 |
Compositions and methods for evaluating viral receptor/co-receptor
usage and inhibitors of virus entry using recombinant virus
assays
Abstract
The invention provides a method for identifying whether a
compound inhibits entry of a virus into a cell which comprises: (a)
obtaining nucleic acid encoding a viral envelope protein from a
patient infected by the virus; (b) co-transfecting into a first
cell (i) the nucleic acid of step (a), and (ii) a viral expression
vector which lacks a nucleic acid encoding an envelope protein, and
which comprises an indicator nucleic acid which produces a
detectable signal, such that the first cell produces viral
particles comprising the envelope protein encoded by the nucleic
acid obtained from the patient; (c) contacting the viral particles
produced in step (b) with a second cell in the presence of the
compound, wherein the second cell expresses a cell surface receptor
to which the virus binds; (d) measuring the amount of signal
produced by the second cell in order to determine the infectivity
of the viral particles; and (e) comparing the amount of signal
measured in step (d) with the amount of signal produced in the
absence of the compound, wherein a reduced amount of signal
measured in the presence of the compound indicates that the
compound inhibits entry of the virus into the second cell.
Inventors: |
Petropoulos, Christos J.;
(Half Moon Bay, CA) ; Parkin, Neil T.; (Belmont,
CA) ; Whitcomb, Jeannette; (San Mateo, CA) ;
Huang, Wei; (Foster City, CA) |
Correspondence
Address: |
JONES DAY
222 EAST 41ST STREET
NEW YORK
NY
10017
US
|
Family ID: |
32474015 |
Appl. No.: |
10/164290 |
Filed: |
June 4, 2002 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
60295871 |
Jun 4, 2001 |
|
|
|
Current U.S.
Class: |
435/5 ;
435/6.13 |
Current CPC
Class: |
C12Q 1/703 20130101;
G01N 33/5091 20130101; C12Q 1/6897 20130101; C12Q 1/70 20130101;
G01N 33/56983 20130101 |
Class at
Publication: |
435/005 ;
435/006 |
International
Class: |
C12Q 001/70; C12Q
001/68 |
Claims
What is claimed is:
1. A method for identifying whether a compound inhibits entry of a
virus into a cell which comprises: (a) obtaining nucleic acid
encoding a viral envelope protein from a patient infected by the
virus; (b) co-transfecting into a first cell (i) the nucleic acid
of step (a), and (ii) a viral expression vector which lacks a
nucleic acid encoding an envelope protein, and which comprises an
indicator nucleic acid which produces a detectable signal, such
that the first cell produces viral particles comprising the
envelope protein encoded by the nucleic acid obtained from the
patient; (c) contacting the viral particles produced in step (b)
with a second cell in the presence of the compound, wherein the
second cell expresses a cell surface receptor to which the virus
binds; (d) measuring the amount of signal produced by the second
cell in order to determine the infectivity of the viral particles;
and (e) comparing the amount of signal measured in step (d) with
the amount of signal produced in the absence of the compound,
wherein a reduced amount of signal measured in the presence of the
compound indicates that the compound inhibits entry of the virus
into the second cell.
2. The method of claim 1, wherein the indicator nucleic acid
comprises an indicator gene.
3. The method of claim 2, wherein the indicator gene is a
luciferase gene.
4. The method of claim 1, wherein the cell surface receptor is
CD4.
5. The method of claim 1, wherein the cell surface receptor is a
chemokine receptor.
6. The method of claim 1, wherein the cell surface receptor is
CXCR4 or CCR5.
7. The method of claim 1, wherein the patient is infected with the
HIV-1 virus.
8. The method of claim 1, wherein the nucleic acid of step (a)
comprises DNA encoding gp120and gp41.
9. The method of claim 1, wherein the viral expression vector
comprises HIV nucleic acid.
10. The method of claim 9, wherein the viral expression vector
comprises an HIV gag-pol gene.
11. The method of claim 9, wherein the viral expression vector
comprises DNA encoding vif, vpr, tat, rev, vpu, and nef.
12. The method of claim 1, wherein the first cell is a mammalian
cell.
13. The method of claim 12, wherein the mammalian cell is a human
cell.
14. The method of claim 13, wherein the human cell is a human
embryonic kidney cell.
15. The method of claim 14, wherein the human embryonic kidney cell
is a 293 cell.
16. The method of claim 1, wherein the second cell is a human T
cell.
17. The method of claim 1, wherein the second cell is a human T
cell leukemia cell line.
18. The method of claim 1, wherein the second cell is a peripheral
blood mononuclear cell.
19. The method of claim 1, wherein the second cell is an
astroglioma cell.
20. The method of claim 19, wherein the astroglioma cell is a U87
cell.
21. The method of claim 1, wherein the second cell is a human
osteosarcoma cell.
22. The method of claim 2, wherein the human osteosarcoma cell is
an HT4 cell.
23. The method of claim 1, wherein the compound binds to the cell
surface receptor.
24. The method of claim 1, wherein the compound is a ligand of the
cell surface receptor.
25. The method of claim 23, wherein the compound comprises an
antibody.
26. The method of claim 1, wherein the compound inhibits membrane
fusion.
27. The method of claim 1, wherein the compound is a peptide, a
peptidomimetic, an organic molecule, or a synthetic compound.
28. The method of claim 1, wherein the compound binds the viral
envelope protein.
29. A method for making a composition which comprises admixing the
compound identified by claim 1 with a carrier.
30. The method of claim 29, wherein the carrier is saline,
polyethylene glycol, a buffer solution, a starch, or an organic
solvent.
31. A method for identifying a cell surface receptor which is bound
by a virus upon infection of a cell by the virus which comprises:
(a) obtaining viral particles which comprise (i) a viral nucleic
acid and (ii) an indicator nucleic acid which produces a detectable
signal; (b) contacting a cell which expresses a cell surface
receptor with the viral particles from step (a); and (c) measuring
the amount of detectable signal produced within the cell, wherein
production of the signal indicates the cell surface receptor
expressed by the cell is bound by the virus, thereby identifying
the cell surface receptor as being bound by the virus upon
infection of the cell.
32. A method for identifying whether an antibody inhibits entry of
a virus into a cell which comprises: (a) obtaining nucleic acid
encoding a viral envelope protein from a patient infected by the
virus; (b) co-transfecting into a first cell (i) the nucleic acid
of step (a), and (ii) a viral expression vector which lacks a
nucleic acid encoding an envelope protein, and which comprises an
indicator nucleic acid which produces a detectable signal, such
that the first cell produces viral particles comprising the
envelope protein encoded by the nucleic acid obtained from the
patient; (c) contacting the viral particles produced in step (b)
with a second cell in the presence of the antibody, wherein the
second cell expresses a cell surface receptor to which the virus
binds; (d) measuring the amount of signal produced by the second
cell in order to determine the infectivity of the viral particles;
and (e) comparing the amount of signal measured in step (d) with
the amount of signal produced in the absence of the compound,
wherein a reduced amount of signal measured in the presence of the
antibody indicates that the antibody inhibits entry of the virus
into the second cell.
33. A method for determining susceptibility of a virus to a
compound which inhibits viral cell entry which comprises: (a)
obtaining nucleic acid encoding a viral envelope protein from a
patient infected by the virus; (b) co-transfecting into a first
cell (i) the nucleic acid of step (a), and (ii) a viral expression
vector which lacks a nucleic acid encoding an envelope protein, and
which comprises an indicator nucleic acid which produces a
detectable signal: such that the first cell produces viral
particles comprising the envelope protein encoded by the nucleic
acid obtained from the patient; (c) contacting the viral particles
produced in step (b) with a second cell in the presence of the
compound, wherein the second cell expresses a cell surface receptor
to which the virus binds; (d) measuring the amount of signal
produced by the second cell in order to determine the infectivity
of the viral particles; and (e) comparing the amount of signal
measured in step (d) with the amount of signal produced in the
absence of the compound, wherein a reduced amount of signal
measured in the presence of the compound indicates that the virus
is susceptible to the compound.
34. A method for determining resistance of a virus to a compound
which inhibits viral entry into a cell which comprises: (a)
determining susceptibility of a virus to a compound according to
the method of claim 33, wherein a nucleic acid encoding a viral
envelope protein is obtained from a patient at a first time; (b)
determining susceptibility of the virus to the compound according
to the method of claim 33, wherein the nucleic acid encoding the
viral envelope protein is obtained from the patient at a later
second time; and (c) comparing the susceptibilities determined in
steps (a) and (b), wherein a decrease in susceptibility at the
later second time indicates resistance of the virus to the
compound.
35. A method for identifying a mutation in a virus that confers
resistance to a compound that inhibits viral entry into a cell
which comprises: (a) determining the nucleic acid sequence or the
amino acid sequence of the virus prior to any treatment of the
virus with the compound; (b) obtaining a virus resistant to the
compound; (c) determining the nucleic acid sequence or the amino
acid sequence of the resistant virus from step (b) and (d)
comparing the nucleic acid sequence or the amino acid sequences of
steps (a) and (c), respectively, so as to identify the mutation in
the virus that confers resistance to the compound.
36. The method of claim 35, wherein the virus obtained in step (b)
is the virus of step (a) grown in the presence of the compound
until resistance is developed.
37. The method of claim 35, wherein the virus obtained in step (b)
is isolated from a patient which has been undergoing treatment with
the compound.
Description
[0001] This application claims priority of U.S. Provisional
Application No. 60/295,871, filed Jun. 4, 2001, the contents of
which are hereby incorporated by reference into this
application.
[0002] Throughout this application, various publications are
referenced by author and date within the text .Full citations for
these publications may be found listed alphabetically at the end of
the specification immediately preceding the claims. All such
publications in their entireties are hereby incorporated by
reference into this application in order to more fully describe the
state of the art as known to those skilled therein as of the date
of the invention described and claimed herein.
BACKGROUND OF THE INVENTION
[0003] Virus entry is an attractive new target for anti-viral
treatment, and about 10 drugs that are designed to block virus
attachment or membrane fusion are currently being evaluated in
preclinical or clinical studies (Richman, 1998; PhRMA, 1999;
Stephenson, 1999). Enveloped animal viruses attach to and enter the
host cell via the interaction of viral proteins in the virion
membrane (envelope proteins) and cell surface proteins (virus
receptors). Receptor recognition and binding are mediated by the
surface envelope protein.
SUMMARY OF THE INVENTION
[0004] Accordingly, it is an object of the invention to provide a
rapid, sensitive phenotypic assay to measure the susceptibility of
a virus to inhibitors of viral entry.
[0005] A further object of the invention is to provide a retroviral
vector system What produces virus particles containing viral
envelope proteins derived from a variety of sources and the
identification of cell lines that express viral receptors and are
permissive for viral replication.
[0006] Another object of the invention is to provide an expression
vector for viral envelope that is capable of accepting
patient-derived segments encoding envelope genes.
[0007] Another object of the invention is to provide a bio-safe
vector that represents most of the HIV-1 viral genome, but carries
a luciferase reporter gene in place of the envelope region.
[0008] A further object of the invention is to the phenotypic assay
which reduces the likelihood of forming recombinant infectious
HIV-1, by providing a viral expression vector that carries a
deletion in a transcriptional regulatory region (the 3' copy of U3)
of the HIV-1 genome.
[0009] Another object of the invention is to provide an assay
capable of identifying and determining receptor/co-receptor
tropism, which quickly and accurately identifies patients that are
infected with strains of a tropic virus.
[0010] These and other objects may be achieved by the present
invention by: a method for identifying whether a compound inhibits
entry of a virus into a cell which comprises: (a) obtaining nucleic
acid encoding a viral envelope protein from a patient infected by
the virus; (b) co-transfecting into a first cell (i) the nucleic
acid of step (a), and (ii) a viral expression vector which lacks a
nucleic acid encoding an envelope protein, and which comprises an
indicator nucleic acid which produces a detectable signal, such
that the first cell produces viral particles comprising the
envelope protein encoded by the nucleic acid obtained from the
patient; (c) contacting the viral particles produced in step (b)
with a secnod cell in the presence of the compound wherein the
second cell expresses a cell surface receptor to which the virus
binds; (d) measuring the amount of signal produced by the second
cell in order to determine the infectivity of the viral particles;
and (e) comparing the amount of signal measured in step (d) with
the amount of signal produced in the absence of the compound,
wherein a reduced amount of signal measured in the presence of the
compound indicates that the compound inhibits entry of the virus
into the second cell.
BRIEF DESCRIPTION OF THE DRAWINGS
[0011] The file of this patent contains at least one drawing
executed in color. Copies of this patent with color drawing(s) will
be provided by the Patent and Trademark Office upon request and
payment of the necessary fee.
[0012] FIG. 1A. Structure of envelope expression and viral
expression vectors.
[0013] The HIV envelope expression vector (pHIUVenv) is modified to
accept envelope sequences that have been amplified from patient
plasma samples. The designations a/b and c/d, refer to restriction
endonuclease sites positioned at the 5' and 3' end of the HIV-1
envelope polyprotein (gp160). The HIV expression vector (pHIVlucU3)
encodes all HIV proteins except the envelope polyprotein. A portion
of the envelope gene has been deleted to accommodate a indicator
gene cassette, in this case, "Firefly Luciferase" that is used to
monitor the ability of the virus to replicate in the presence or
absence of anti-viral drugs. The 3' U3 region has been partially
deleted to prevent transcription from the 5' LTR in infected cells.
Virus produced in this system is limited to a single round of
replication.
[0014] FIG. 1B. Cell Based Entry Assay
[0015] Drug susceptibility, co-receptor tropism and virus
neutralization testing are performed by co-transfecting a host cell
with pHIVenv and pHIVlucU3. The host cell produces HIV particles
that are pseudo-typed with HIV envelope sequences derived from the
test virus or patient sample. Virus particles are collected
(.about.48 h) after transfection and are used to infector target
cells that express HIV receptors (e.g. CD4) and co-receptors (e.g.
CXCR4, CCRS). After infection (.about.72 h) the target cells are
lysed and luciferase activity is measured. HIV must complete one
round of replication to successfully infect the target host cell
and produce luciferase activity. If the virus is unable to enter
the target cell, luciferase activity is diminished. This system can
be used to evaluate susceptibility to entry inhibitors, receptor
and co-receptor tropism, and virus neutralization.
[0016] FIG. 2. HIV envelope expression vectors.
[0017] HIV envelope sequences are amplified from patient samples
and inserted into expression vectors using restriction endonuclease
sites (5' a/b and 3'c/d). Envelope transcription is driven by the
immediate early gene promoter of human cytomegalovirus (CMV).
Envelope RNA is polyadenylated using an simian virus 40 (SV40)
polyadenylation signal sequence (A+). An intron located between the
CMV promoter and the HIV envelope sequences is designed to increase
envelope mRNA levels in transfected cells. FL-express full-length
envelope proteins (gp120, gp41) CT-express envelope proteins
(gp120, gp21) lacking the C-terminal cytoplasmic tail domain of
gp41+CT-express envelope proteins (gp120, gp41) containing a
constant pre-defined gp41 cytoplasmic tail domain gp120-express
gp120 proteins derived from the patient together with a constant
pre-defined gp41. gp41express a constant pre-defined gp120 together
with gp41proteins derived from the patient.
[0018] FIG. 3A. Co-receptor Tropism Screening Assay.
[0019] In this figure, the assay is performed using two cell lines.
One cell line expresses CD4 and CCR5 (top six panels). The other
cell line expresses CD4 and CXCR4 (bottom six panels). The assay is
performed by infecting cells with a large number of recombinant
virus stocks derived from cells transfected with pHIVenv and
pHIVluc?U3 vectors. The example shown represents the analysis of 96
viruses formatted in a 96 well plate Infections are performed in
the absence of drug (no drug), or in the presence of a drug that
preferentially inhibits either R5 tropic (CCR inhibitor) or X4
tropic (CXCR4 inhibitor) viruses. Co-receptor tropism is assessed
by comparing the amount of luciferase activity produced in each
cell type, both in the presence and absence of drug (see FIG. 3B
for interpretation of assay results).
[0020] FIG. 3B. Determining co-receptor tropism.
[0021] In this figure, the results of the assay are interpreted by
comparing the ability of each sample virus to infect (produce
luciferase activity) in cells expressing CD4/CCR5 (R5 cells) or
cells expressing CD4/CXCR4 (X4 cells). The ability of a CCR5 or
CXCR4 inhibitor to specifically block infection (inhibit luciferase
activity) is also evaluated. X4 tropic viruses (green
panels)--infect X4 cells but not R5 cells. Infection of X4 cells is
blocked by the CXCR4 inhibitor . R5 tropic viruses (blue
panels)--infect R5 cells but not X4 cells. Infection of R5 cells is
blocked by the CCR5 inhibitor. Dual tropic or X4/R5 mixtures
(yellow panels)--infect X4 and R5 cells. Infection of R5 cells is
blocked by the CCR5 inhibitor and infection of X4 cells is blocked
by the CXCR4 inhibitor. Non-viable viruses (red panels)--do not
replicate in either X4 or R5 cells.
[0022] FIG. 4A. Measuring Entry Inhibitor Susceptibility: Fusion
Inhibitor.
[0023] In this figure, susceptibility to the fusion inhibitor T-20
is demonstrated. Cells expressing CD4, CCR5 and CXCR4 were infected
in the absence of T-20 and over a wide range of T-20 concentrations
(x-axis log10 scale). The percent inhibition of viral replication
(y-axis) was determined by comparing the amount of luciferase
produced in infected cells in the presence of T-20 to the amount of
luciferase produced in the absence of T-20. R5 tropic, X4 tropic
and dual tropic viruses were tested. Drug susceptibility is
quantified by determining the concentration of T-20 required to
inhibit 50% of viral replication (IC50, shown as vertical dashed
lines). Viruses with lower IC50 values are more susceptible to T-20
than viruses with higher IC50 values. NL4-3: well-characterized X4
tropic strain JRCSF: well-characterized RS tropic strain
91US005.11: R5 tropic isolate obtained from the NIH AIDS Research
and Reference Reagent Program (ARRRP) 92HT593.1: Dual tropic (X4R5)
isolate obtained from the NIH ARRRP.92HT599.24: X4 tropic isolate
obtained from the NIH ARRRP.
[0024] FIG. 4B. Measuring Entry Inhibitor Susceptibility: Drug
Resistance Mutations.
[0025] In this figure, reduced susceptibility to the fusion
inhibitor T-20 conferred by specific drug resistance mutations in
the gp41envelope protein is demonstrated. Cells expressing CD4,
CCR5 and CXCR4 were infected in the absence of T-20 and over a wide
range of T-20 concentrations (x-axis log10 scale). The percent
inhibition of viral replication (y-axis) was determined by
comparing the amount of luciferase produced in infected cells in
the presence of T-20 to the amount of luciferase produced in the
absence of T-20. Isogenic viruses containing one or two specific
mutations in the gp41transmembrane envelope protein were tested
(highlighted in red in the figure legend). Drug susceptibility is
quantified by determining the concentration of T-20 required to
inhibit 50% of viral replication (IC50, shown as vertical dashed
lines). Viruses with lower IC50 values are more susceptible to T-20
than viruses with higher IC50 values.
[0026] No mutation (wildtype sequence): GIV
[0027] Single mutations: GIV, DIM, SIV
[0028] Double mutations: DIM, SIM, DTV
[0029] FIG. 5A.
[0030] Measuring Entry Inhibitor Susceptibility: CCR5 Inhibitor
[0031] In this figure, susceptibility to a CCR5 inhibitor (merck
compound) is demonstrated. Cells expressing CD4 and CCR5 (R5 cells)
were infected in the absence of the CCR5 inhibitor and over a wide
range of CCR5 inhibitor concentrations (x-axis log10 scale). The
percent inhibition of viral replication (y-axis) was determined by
comparing the amount of luciferase produced in infected cells in
the presence of CCR5 inhibitor to the amount of luciferase produced
in the absence of CCR5 inhibitor. R5 tropic, X4 tropic and dual
tropic viruses were tested. Drug susceptibility is quantified by
determining the concentration of CCR5 inhibitor required to inhibit
50% of viral replication (IC50, shown as vertical dashed lines).
Viruses wish lower IC50 values are more susceptible to the CCR5
inhibitor than viruses with higher IC50 values. The X4 tropic virus
did not infect the R5 cells. NL4-3: well-characterized X4 tropic
strain JRCSF: well-characterized R5 tropic strain 92HT593.1: Dual
tropic (X4R5) isolate obtained from the NIH ARRRP.
[0032] FIG. 5B.
[0033] Measuring Entry Inhibitor Susceptibility: CXCR4
Inhibitor.
[0034] In this figure, susceptibility to a CXCR4 inhibitor
(AMD3100) is demonstrated. Cells expressing CD4 and CXCR4 (X4
cells) were infected in the absence of the CXCR4 inhibitor and over
a wide range of CXCR4 inhibitor concentrations (x-axis log10
scale). The percent inhibition of viral replication (y-axis) was
determined by comparing the amount of luciferase produced in
infected cells in the presence of CXCR4 inhibitor to the amount of
luciferase produced in the absence of CXCR4 inhibitor. R5 tropic,
X4 tropic and dual tropic viruses were tested. Drug susceptibility
is quantified by determining the concentration of CXCR4 inhibitor
required to inhibit 50% of viral replication (IC50, shown as
vertical dashed lines) Viruses with lower IC50 values are more
susceptible to the CCR5 inhibitor than viruses with higher IC50
values. The R5 tropic virus did not infect the X4 cells.
[0035] NL4-3: well-characterized X4 tropic strain
[0036] JRCSF: well-characterized R5 tropic strain
[0037] 92HT593.1: Dual tropic (X4R5) isolate obtained from the NIH
ARRRP.
[0038] FIG. 6. Entry Inhibitor Susceptibility: Fusion Inhibitor
[0039] This figure demonstrates that the amplicons corresponding to
the full length envelope sequence or cytoplasmic-tail deleted
envelope sequence are generated. The lane numbers correspond to the
co-receptor tropism shown next to each number on the right of the
gels.
[0040] FIG. 7. Reduced Susceptibility: Fusion Inhibitor
[0041] Scatter plots are shown which indicate the results from FACS
(fluorescence activated cell sorting) assays using antibodies
against either CCR5 or CXCR4 (shown on Y axis) . The cell lines
express the co-receptors listed below the plots and the CD4
fluorescence is shown along the X-axis. The anti-CXCR4 antibody
binds most strongly with the cells which express the corresponding
co-receptor, CXCR-4.
[0042] FIG. 8. Entry Inhibitor Susceptibility: CCR5 Inhibitor
[0043] Inhibition is shown following administration of co-receptor
antagonists.
[0044] FIG. 9. Entry inhibitor susceptibility: CXCR4 Inhibitor Map
and amino acid sequence is shown for a peptide which is an
inhibitor of fusion between a viral membrane and a cell
membrane.
[0045] FIG. 10. Inhibition by Co-Receptor Antagonists
[0046] FIG. 11. T20 Resistance Mutations
[0047] FIG. 12. Identifying Entry Inhibitor Resistance
Mutations
[0048] FIG. 13. Fusion Inhibitor Peptides
[0049] The invention in its particular features cain become more
apparent from the following detailed description considered with
reference to the accompanying figures and examples. The following
description discusses the means and methods to carry out the
present invention pertaining to a phenotypic assay relating to
identifying and evaluating inhibitors of viral entry, including for
example, and not as a limitation to the present invention, HIV-1
and inhibitors to HIV-1 viral entry.
DETAILED DESCRIPTION OF THE INVENTION
[0050] This invention provides a method for identifying whether a
compound inhibits entry of a virus into a cell which comprises: (a)
obtaining nucleic acid encoding a viral envelope protein from a
patient infected by the virus; (b) co-transfecting into a first
cell (i) the nucleic acid of step (a), and (ii) a viral expression
vector which lacks a nucleic acid encoding an envelope protein, and
which comprises an indicator nucleic acid which produces a
detectable signal, such that the first cell produces viral
particles comprising the envelope protein encoded by the nucleic
acid obtained from the patient; (c) contacting the viral particles
produced in step (b) with a second cell in the presence of the
compound, wherein the second cell expresses a cell surface receptor
to which the virus binds; (d) measuring the amount of signal
produced by the second cell in order to determine the infectivity
of the viral particles; and (e) comparing the amount of signal
measured in step (d) with the amount of signal produced in the
absence of the compound, wherein a reduced amount of signal
measured in the presence of the compound indicates that the
compound inhibits entry of the virus into the second cell.
[0051] In one embodiment of this invention, the indicator nucleic
acid comprises an indicator gene. In another embodiment of this
invention, the indicator gene is a luciferase gene.
[0052] In one embodiment of this invention, the cell surface
receptor is CD4. In one embodiment of this invention, the cell
surface receptor is a chemokine receptor. In one embodiment of this
invention, the cell surface receptor is CXCR4 or CCR5.
[0053] In one embodiment of this invention, the patient is infected
with the HIV-1 virus, a hepatitis virus (such as the HCV or HBV
virus), or any other virus.
[0054] In one embodiment of this invention, the nucleic acid of
step (a) comprises DNA encoding gp120 and gp41.
[0055] In one embodiment of this invention, the viral expression
vector comprises HIV nucleic acid.
[0056] In one embodiment of this invention, the viral expression
vector comprises an HIV gag-pol gene.
[0057] In one embodiment of this invention, the viral expression
vector comprises DNA encoding vif, vpr, tat, rev, vpu, and nef.
[0058] In one embodiment of this invention, the first cell is a
mammalian cell.
[0059] In one embodiment of this invention, the mammalian cell is a
human cell.
[0060] In one embodiment of this invention, the human cell is a
human embryonic kidney cell.
[0061] In one embodiment of this invention, the human embryonic
kidney cell is a 293 cell.
[0062] In one embodiment of this invention, the second cell is a
human T cell.
[0063] In one embodiment of this invention, the second cell is a
human T cell leukemia cell line.
[0064] In one embodiment of this invention, the second cell is a
peripheral blood mononuclear cell.
[0065] In one embodiment of this invention, the second cell is an
astroglioma cell.
[0066] In one embodiment of this invention, the astroglioma cell is
a U87 cell.
[0067] In one embodiment of this invention, the second cell is a
human osteosarcoma cell.
[0068] In one embodiment of this invention, the human osteosarcoma
cell is an HT4 cell.
[0069] In one embodiment of this invention, the compound binds to
the cell surface receptor.
[0070] In one embodiment of this invention, the compound is a
ligand of the cell surface receptor.
[0071] In one embodiment of this invention, the compound comprises
an antibody.
[0072] In one embodiment of this invention, the compound inhibits
membrane fusion.
[0073] In one embodiment of this invention, the compound is a
peptide, a peptidomimetic, an organic molecule, or a synthetic
compound.
[0074] In one embodiment of this invention, the compound binds the
viral envelope protein.
[0075] This invention provides for a method for making a
composition which comprises admixing the compound identified by the
screening method (method for identifying a compound) described
herein with a carrier.
[0076] In one embodiment of this invention, the carrier is saline,
polyethylene glycol, a buffer solution, a starch, or an organic
solvent.
[0077] The invention provides for a method for identifying a cell
surface receptor which is bound by a virus upon infection of a cell
by the virus which comprises: (a) obtaining viral particles which
comprise (i) a viral nucleic acid and (ii) an indicator nucleic
acid which produces a detectable signal; (b) contacting a cell
which expresses a cell surface receptor with the viral particles
from step (a); and (c) measuring the amount of detectable signal
produced within the cell, wherein production of the signal
indicates the cell surface receptor expressed by the cell is bound
by the virus, thereby identifying the cell surface receptor as
being bound by the virus upon infection of the cell.
[0078] The invention also provides for a method for identifying
whether an antibody inhibits entry of a virus into a cell which
comprises: (a) obtaining nucleic acid encoding a viral envelope
protein from a patient infected by the virus; (b) co-transfecting
into a first cell (i) the nucleic acid of step (a), and (ii) a
viral expression vector which lacks a nucleic acid encoding an
envelope protein, and which comprises an indicator nucleic acid
which produces a detectable signal, such that the first cell
produces viral particles comprising the envelope protein encoded by
the nucleic acid obtained from the patient; (c) contacting the
viral particles produced in step (b) with a second cell in the
presence of the antibody, wherein the second cell expresses a cell
surface receptor to which the virus binds; (d) measuring the amount
of signal produced by the second cell in order to determine the
infectivity of the viral particles; and (e) comparing the amount of
signal measured in step (d) with the amount of signal produced in
the absence of the compound, wherein a reduced amount of signal
measured in the presence of the antibody indicates that the
antibody inhibits entry of the virus into the second cell.
[0079] The invention provides for a method for determining
susceptibility of a virus to a compound which inhibits viral cell
entry which comprises: (a) obtaining nucleic acid encoding a viral
envelope protein from a patient infected by the virus; (b)
co-transfecting into a first cell (i) the nucleic acid of step (a),
and (ii) a viral expression vector which lacks a nucleic acid
encoding an envelope protein, and which comprises an indicator
nucleic acid which produces a detectable signal, such that the
first cell produces viral particles comprising the envelope protein
encoded by the nucleic acid-obtained.,from -he patient; (c)
contacting the viral particles produced in step (b) with a second
cell in the presence of the compound, wherein the second cell
expresses a cell surface receptor to which the virus binds; (d)
measuring the amount of signal produced by the second cell in order
to determine the infectivity of the viral particles; and (e)
comparing the amount of signal measured in step (d) with the amount
of signal produced in the absence of the compound, wherein a
reduced amount of signal measured in the presence of the compound
indicates that the virus is susceptible to the compound.
[0080] The invention provides a method for determining resistance
of a virus to a compound which inhibits viral entry into a cell
which comprises: (a) determining susceptibility of a virus to a
compound according to the method of claim 33, wherein a nucleic
acid encoding a viral envelope protein is obtained from a patient
at a first time; (b) determining susceptibility of the virus to the
compound according to the method of claim 33, wherein the nucleic
acid encoding the viral envelope protein is obtained from the
patient at a later second time; and (c) comparing the
susceptibilities determined in steps (a) and (b), wherein a
decrease in susceptibility at the later second time indicates
resistance of the virus to the compound.
[0081] The invention provides for a method for identifying a
mutation in a virus that confers resistance to a compound that
inhibits viral entry into a cell which comprises: (a) determining
the nucleic acid sequence or the amino acid sequence of the virus
prior to any treatment of the virus with the compound; (b)
obtaining a virus resistant to the compound; (c) determining the
nucleic acid sequence or the amino acid sequence of the resistant
virus from step (b); and (d) comparing the nucleic acid sequence or
the amino acid sequences of steps (a) and (c), respectively, so as
to identify the mutation in the virus that confers resistance to
the compound.
[0082] In one embodiment of this invention, the virus obtained in
step (b) is the virus of step (a) grown in the presence of the
compound until resistance is developed.
[0083] In one embodiment of this invention, the virus obtained in
step (b) is isolated from a patient which has been undergoing
treatment with the compound.
[0084] In a preferred embodiment, this invention provides a means
and method for accurately and reproducibly measuring the
susceptibility of HIV-1 to virus entry inhibitors.
[0085] In another preferred embodiment, this invention also
provides a means and method for accurately and reproducibly
measuring HIV-1 co-receptor tropism.
[0086] In a preferred embodiment, this invention provides a means
and method for accurately and reproducibly measuring antibody
mediated neutralization of HIV-1.
[0087] In a preferred embodiment, this invention further provides a
means and method for discovering, optimizing and characterizing
novel or new drugs that target various defined and as yet undefined
steps in the virus attachment and entry process.
[0088] In a preferred embodiment, this invention further provides a
means and method for discovering, optimizing and characterizing
HIV-1 vaccines (either preventative or therapeutic) that target
various defined and as yet undefined steps in the virus attachment
and entry process.
[0089] In a preferred embodiment, this invention provides a means
and method for identifying amino acid substitutions/mutations in
HIV-1 envelope proteins (gp41TM and gp120SU) that alter
susceptibility to inhibitors of virus entry.
[0090] In a preferred embodiment, this invention provides a means
and method for quantifying the affect that specific mutations in
HIV-1 envelope have on virus entry inhibitor susceptibility.
[0091] In a preferred embodiment, this invention further provides a
means and method for determining HIV-1 envelope amino acid
substitutions/mutations that are frequently observed, either alone
or in combination, in viruses that exhibit altered susceptibility
to virus entry inhibitors.
[0092] In a preferred embodiment, this invention provides a means
and method for identifying amino acid substitutions/mutations in
HIV-1 envelope proteins (gp41TM and gp120SU) that alter receptor or
co-receptor tropism.
[0093] In a preferred embodiment, this invention provides a means
and method for quantifying the affect that specific mutations in
HIV-1 envelope have receptor or co-receptor tropism.
[0094] In a preferred embodiment, this invention further provides a
means and method for identifying HIV-1 envelope amino acid
substitutions/mutations that are frequently observed, either alone
or in combination, in viruses that exhibit CXCR4 or CCR5
co-receptor tropism.
[0095] In a preferred embodiment, this invention provides a means
and method for identifying amino acid substitutions/mutations in
HIV-1 envelope proteins (gp41TM and gp120SU) that alter antibody
mediated neutralization.
[0096] In a preferred embodiment, this invention provides a means
and method for quantifying the affect that specific mutations in
HIV-1 envelope have on antibody mediated neutralization.
[0097] In a preferred embodiment, this invention further provides a
means and method for identifying HIV-1 envelope amino acid
substitutions/mutations that are frequently observed, either alone
or in combination, in viruses that exhibit antibody medicated virus
neutralization.
[0098] In a preferred embodiment, this invention further provides a
means and method to identify antibodies that are frequently
observed in patient samples viruses that are capable of
neutralizing HIV-1.
[0099] In a preferred embodiment, this invention further provides a
means and method for identification of viruses that require CD4
binding for infection.
[0100] In a preferred embodiment, this invention further provides a
means and method for the identification of viruses that do not
require CD4 binding for infection.
[0101] In a preferred embodiment, this invention also provides a
means and method for identifying the incidence of patient samples
that exhibit CD4 independent infection.
[0102] In a preferred embodiment, this invention further provides a
means and method for identification of viruses that require CD8
binding for infection.
[0103] In a preferred embodiment, this invention also provides a
means and method for identifying the incidence of patient viruses
that exhibit CD8 dependent infection.
[0104] In a preferred embodiment, this invention further provides
the means and method for the identification of viruses that require
the CXCR4 chemokine receptor binding, the CCR5 chemokine receptor
binding, or either CXCR4 or CCR5 binding (dual tropic) for
infection.
[0105] In a preferred embodiment, this invention further provides a
means and method for identifying the incidence of viruses teat
require the CXCR4 chemokine receptor binding, the CCR5 chemokine
receptor binding, or either CXCR4 or CCR5 binding (dual tropic) for
infection.
[0106] In a preferred embodiment, this invention further provides a
means and method for identifying HIV-1 envelope amino acid
substitutions/mutations that are frequently observed, either alone
or in combination, in viruses that exhibit (a) altered
susceptibility to virus entry inhibitors, (b) CXCR4 or CCR5
co-receptor tropism, and (c) antibody medicated virus
neutralization.
[0107] In a preferred embodiment, this invention provides a means
and method for using virus entry inhibitor susceptibility to guide
the treatment of HIV-1.
[0108] In a preferred embodiment, this invention further provides a
means and method for using virus entry inhibitor susceptibility to
guide the treatment of patients failing antiretroviral drug
treatment.
[0109] In a preferred embodiment, this invention further provides
the means and methods for using virus entry inhibitor
susceptibility to guide the treatment of patients newly infected
with HIV-1.
[0110] In a preferred embodiment, this invention provides a means
and method for using HIV-1 co-receptor tropism to guide the
treatment of HIV-1 or to guide the treatment of patients failing
antiretroviral drug treatment.
[0111] In a preferred embodiment, this invention further provides
the means and method for using HIV-1 co-receptor tropism to guide
the treatment of patients newly infected with HIV-1.
[0112] In a preferred embodiment, this invention further provides a
means and method for measuring antibody mediated neutralization of
HIV-1 to monitor the initial protective antibody response following
vaccination.
[0113] In a preferred embodiment, this invention further provides a
means and method for measuring antibody mediated neutralization of
HIV-1 to monitor the initial therapeutic antibody response
following vaccination.
[0114] In a preferred embodiment, this invention further provides a
means and method for measuring antibody mediated neutralization of
HIV-1 over time to monitor the durability of a protective antibody
response following vaccination.
[0115] In a preferred embodiment, this invention further provides a
means and method for measuring antibody mediated neutralization of
HIV-1 to develop and optimize vaccination prime-boost schedules
that maximize vaccination potency and durability.
[0116] For example, in the case of HIV-1, the SU protein (gp120-SU)
is tightly associated with the transmembrane envelope protein
(gp41-TM) that anchors the complex to the virus membrane. The
envelope proteins gp120 and gp41 are derived by cleavage of gp160,
the uncleaved precursor product of the envelope gene. The binding
of HIV-1 to its cellular receptor (CD4) and co-receptor (either
CCR5 or CXCR4) promotes conformational changes in the TM protein
resulting in the fusion of the viral and cellular membrane and
entry of the virus core into the cytoplasm (Retroviruses, 1997).
Although the new HIV entry inhibitors target either viral envelope
proteins (gp120/gp41) or host proteins (CD4, CCR5, CXCR4), the
majority of resistance-associated mutations in HIV-1 are expected
to be located in the viral envelope gene; e.g. one likely way
viruses might evolve is to shift co-receptor utilization. Entry
blockers constitute a novel class of anti-retroviral drugs, and the
potential for broad activity against current multi-drug resistant
HIV-1 variants is high. Among the class of potential viral entry
blockers are fusion inhibitors, receptor/co-receptor antagonists
and vaccines.
[0117] Nonetheless, inhibitors of viral entry are likely to
generate drug resistant viruses (through mutation of the envelope
gene), thus complicating patient treatment similar to that observed
for protease inhibitor (PRI) and reverse transcriptase inhibitor
(PTI) treatment for HIV. In fact, FDA approval of any new drug that
blocks viral entry will require the evaluation of resistance data.
The need for a diagnostic assay that measures susceptibility to
entry blockers has been documented in the case of the fusion
inhibitor T-20. Viruses exhibiting reduced susceptibility to T-20
have been reported after passage in vitro in the presence of the
drug. At this time, convenient phenotypic assays that are capable
of measuring susceptibility to drugs that block viral entry are not
available. Consequently physicians will soon be faced with the
challenge of tailoring therapy in the absence of the tools
necessary to address drug susceptibility. Therefore, a reliable
assay that accurately measures susceptibility to drugs that inhibit
viral entry from infected patients would be extremely valuable.
[0118] For example, recent World Health Organization estimates
indicate that worldwide more than 33 million people are infected
with HIV-1, the causative agent for the AIDS pandemic. Nearly one
million people are infected in the United States and 300,000 are
currently receiving anti-viral therapy (CDC, 1999; WHO 1999).
Combating AIDS has become the common goal of an unprecedented
effort of governmental agencies, academic laboratories, and the
pharmaceutical/biotechnology industry. Fourteen anti-viral drugs
have been approved by the FDA for treatment of HIV-1 infection
(carpenter et al., 2000) and more than 20 additional drugs are
currently being evaluated in clinical trials (PHRMA, 1999). The
approved drugs inhibit HIV-1 replication by interfering with the
enzymatic activities of either protease (PR) or reverse
transcriptase (RT). PR inhibitors (PRIs) block the proper formation
of viral proteins that are necessary for virus infection and
replication, while RT inhibitors (RTIs) block the virus from
copying its genetic material. Due to sub-optimal potency, current
PRIs and RTIs are most often used in combination to suppress viral
replication (Carpenter et al., 2000).
[0119] What is desired, therefore, is to provide a rapid, accurate
safe viral assay capable of evaluating:
[0120] 33. the activity of inhibitors of viral attachment and entry
(including fusion, receptor and co-receptor inhibitors);
[0121] 34. receptor/co-receptor viral tropism to facilitate viral
entry inhibitor drug design and treatment;
[0122] 35. changes in drug susceptibility of patient viruses to
inhibitors of attachment and entry; and
[0123] 36. viral neutralizing activity generated in response to
vaccination using viral envelope protein antigens.
[0124] The methods of this invention can be used for any viral
disease that may be responsive to a viral entry inhibitor and where
anti-viral drug susceptibility and resistance to a viral entry
inhibitor is a concern including, for example, including, but not
limited to other lentiviruses (e.g. HIV-2), other retroviruses
(e.g. HTLV-1 and 2), hepadnaviruses (e.g. human hepatitis B virus)
flaviviruses (e.g. human hepatitis C virus) and herpesviruses (e.g.
human cytomegalovirus).
[0125] Entry blockers constitute a novel class of anti-retroviral
drugs, and the potential for broad activity against current
multi-drug resistant HIV-1 variants is high. Among the class of
potential viral entry blockers are fusion inhibitors,
receptor/co-receptor antagonists and vaccines.
[0126] Fusion Inhibitors
[0127] Compounds designed to competitively inhibit the
conformational change of TM, designated fusion inhibitors, are
potent inhibitors of HIV-1 replication. Although their activity has
been demonstrated both in cell culture systems and HIV-1 infected
patients (Wild et al., 1992; Judice et al., 1997; Kilby et al.,
1998), no fusion inhibitor has yet been approved for the treatment
of HIV-1 infection in the U.s. Drugs within this class, such as
t-20 and t-1249 (Trimeris Inc., USA), are the subject of advanced
clinical investigations.
[0128] Receptor/Co-receptor Antagonists
[0129] In addition to fusion inhibitors, which act after HIV-1 has
interacted with its receptors, efforts are in progress to develop
drugs that prevent HIV-1 from interacting with CD4 or either of its
two principal co-receptors. The ability of such reagents to inhibit
HIV-1 infection has been demonstrated in cell culture systems and
animal models. Lead compounds targeting either gp120, CD4, the CCR5
co-receptor used by macrophage tropic viruses (R5), or the CXCR4
co-receptor used by T-cell tropic viruses (X4) have been identified
(Allaway et al., 1993; Reimann et al., 1995; Baba et al., 1999;
Bridger et al., 1999).
[0130] Currently, no co-receptor antagonists are approved for the
treatment of HIV-1 infection in the U.S. Drugs within these
classes, such as PRO 542 (Progenics Inc., USA), 5a8 (Tanox, USA),
TAK-779 (Takeda Inc., Japan), and AMD-3100 (Anormed Inc., Canada),
are the subjects of preclinical or early stage clinical
investigations. Therefore, an assay capable of identifying and
determining receptor/co-receptor tropism, which quickly and
accurately identifies patients that are infected with strains of a
tropic virus (e.g. HIV-1), would facilitate viral entry inhibitor
drug design and treatment.
[0131] Vaccines
[0132] Vaccines have also proven to be an effective strategy in the
fight against pathogenic viral infections in humans, and several
vaccine candidates to prevent HIV-1 infection are in clinical
development. The envelope proteins gp120and gp41are the most
obvious candidates in the intense search for an HIV-1 vaccine, and
many of the 11 vaccine candidates in clinical evaluation are
envelope-based (PhRMA, 1999). It is generally thought that an
effective envelope vaccine may elicit the generation of
neutralizing antibodies that block viral infection (Mascola et al.,
2000). Therefore, a sensitive high-throughput assay that reliably
measures the efficacy of such neutralizing antibodies and does not
require prolonged cultivation of virus is urgently needed. Such an
assay could significantly aid the search for an effective AIDS
vaccine. This is particularly true, considering that late-stage
clinical trials encompass large patient populations numbering in
the thousands. Since neutralizing antibodies should prevent
successful infection of target cells, a envelope receptor assay
would be beneficial to serve as a virus neutralization assay.
[0133] Unfortunately, most of these drug combinations are effective
for only a limited time in large part due to the emergence of drug
resistant viruses. The lack of proofreading functions inherent to
RT and RNA polymerase II, coupled with high level, error-prone
replication allows viruses such as HIV-1 to mutate readily (Coffin,
1995). This high mutation frequency contributes to the ability of
HIV-1 to evade successful long-term drug therapy, resulting in
viral load rebound. Resistance-associated mutations to all of the
14 approved drugs as well as to many investigational compounds have
been described (Schinazi et al., 1999). Consequently, multi-drug
resistant HIV-1 variants pose an increasing problem in the care of
infected patients. To achieve long-term clinical benefit, it is
desirable to select those drugs that maximally suppress viral
replication and avoid the drugs to which a patient's virus is
resistant (DHHs, 2000). Long-term solutions can rely on drug
resistance tests that can guide physicians in selecting the most
effective drugs against the patient's virus. The need for
resistance testing has been affirmed in recent guidelines from the
DHHs (DHHs, 2000), recommending that resistance tests be routinely
used when treating HIV-1 infected patients. Susceptibility tests
can also assist in the development of new drugs that target
resistant viruses. A recent FDA advisory committee (November 1999)
recommended that resistance testing be used in the development of
new anti-viral drugs for HIV-1.
[0134] Several strategies have been applied to the assessment of
antiviral drug susceptibility. Genotypic tests analyze mutations in
the underlying nucleotide sequence, or genotype, and attempt to
correlate these mutations with drug resistance (Rodriguez-Rosado et
al., 1999; Schirazi et. al, 1999). However, the relationship
between genotype and phenotype is complex and not easily
interpreted, and the results of these tests are not quantitative.
The use of genotypic drug susceptibility data requires
interpretation either by experts (Baxter et al., 1999) or computer
algorithms and are not always predictive of treatment outcome
(Piketty et al., 1999).
[0135] Phenotypic drug susceptibility assays directly measure and
quantify the ability of viruses to replicate in the presence of
drug. Early phenotypic tests required prolonged virus cultivation
and consequently were slow, labor intensive, and not easily
automated for high throughput (Japour et al., 1993). As a result,
these early phenotypic tests were considered impractical for
patient management. The development of recombinant virus assays
(Shi and Mellors, 1997; Hertogs et al., 1998) simplified phenotypic
testing and increased throughput. However, a major disadvantage of
these assays is a lengthy turnaround time of 4-8 weeks. More
recently, recombinant virus assays have been developed and others
that are capable of measuring drug susceptibility during a single
round of replication (Zennou et al., 1998; Petropoulos et al.,
2000), resulting in a dramatic reduction in turnaround time to 8-10
days. Patients failing anti-retroviral therapy can benefit from
phenotypic assays. Such assays are attractive tools for patient
management because they provide a direct and rapid measure of drug
susceptibility.
[0136] The assay of this invention can be used with other viral
infections arising from Infections due to other viruses within
these families as well as viral infections arising from viruses in
other viral families. In addition, the drug susceptibility and
resistance test of this invention is useful for screening for
compounds to treat viral diseases for which there is no currently
available therapy.
[0137] The structure, life cycle and genetic elements of the
viruses which could be tested in the drug susceptibility and
resistance test of this invention would be known to one of ordinary
skill in the art. It is useful to the practice of this invention,
for example, to understand the life cycle of a retrovirus, as well
as the viral genes required for retrovirus rescue and infectivity.
Retrovirally infected cells shed a membrane virus containing a
diploid RNA genome. The virus, studded with an envelope
glycoprotein (which serves to determine the host range of
infectivity), attaches to a cellular receptor in the plasma
membrane of the cell to be infected. After receptor binding, the
virus is internalized and uncoated as it passes through the
cytoplasm of the host cell. Either on its way to the nucleus or in
the nucleus, the reverse transcriptase molecules resident in the
viral core drive the synthesis of the double-stranded DNA provirus,
a synthesis that is primed by the binding of a tRNA molecule to the
genomic viral RNA. The double-stranded DNA provirus is subsequently
integrated in the genome of the host cell, where it can serve as a
transcriptional template for both mRNAs encoding viral proteins and
virion genomic RNA, which will be packaged into viral core
particles. On their way out of the infected cell, core particles
move through the cytoplasm, attach to the inside of the plasma
membrane of the newly infected cell, and bud, taking with them
tracts of membrane containing the virally encoded envelope
glycoprotein gene product. This cycle of infection reverse
transcription, transcription, translation, virion assembly, and
budding repeats itself over and over again as infection
spreads.
[0138] The viral RNA and, as a result, the proviral DNA encode
several cis-acting elements that are vital to the successful
completion of the viral lifecycle. The virion RNA carries the viral
promoter at its 3' end. Replicative acrobatics place the viral
promoter at the 5' end of the proviral genome as the genome is
reverse transcribed. Just 3' to the 5' retroviral LTR lies the
viral packaging site. The retroviral lifecycle requires the
presence of virally encoded transacting factors. The
viral-RNA-dependent DNA polymerase (pol)--reverse transcriptase is
also contained within the viral core and is vital to the viral life
cycle in that it is responsible for the conversion of the genomic
RNA to the integrative intermediate proviral DTN. The viral
envelope glycoprotein, env, is required for viral attachment to the
uninfected cell and for viral spread. There are also
transcriptional trans-activating factors, so called
transactivators, that can serve to modulate the level of
transcription of the integrated parental provirus. Typically,
replication-competent (non-defective) viruses are self-contained in
that they encode all of these trans-acting factors. Their defective
counterparts are not self-contained.
[0139] In the case of a DNA virus, such as a hepadnavirus,
understanding the life cycle and viral genes required for infection
is useful to the practice of this invention. The process of HBV
entry has not been well defined. Replication of HBV uses an RNA
intermediate template. In the infected cell the first step in
replication is the conversion of the asymmetric relaxed circle DNA
(rc-DNA) to covalently closed circle DNA (cccDNA). This process
which occurs within the nucleus of infected liver cells, involves
completion of the DNA positive-strand synthesis and ligation of the
DNA ends. In the second step, the cccDNA is transcribed by the host
RNA polymerase to generate a 3.5 kB RNA template (the pregenome).
This pregenome is complexed with protein in the viral core. The
third step involves the synthesis of the first negative sense DNA
strand by copying the pregenomic RNA using the virally encoded P
protein reverse transcriptase. The P protein also serves as the
minus strand DNA primer. Finally, the synthesis of the second
positive-sense DNA strand occurs by copying the first DNA strand,
using the P protein DNA polymerase activity and an oligomer of
viral RNA as primer. The pregenome also transcribes mRNA for the
major structural core proteins.
[0140] Design and Methods
[0141] 37) Construction of an Expression Vector for a Viral
Envelope Protein That is Capable of Accepting Patient-Derived
Segments Encoding the Envelope Protein.
[0142] In one embodiment, an envelope expression vector capable of
expressing HIV-1 envelope proteins in transfected cells was
constructed. Similar expression vectors have been described,
including a plasmid (pAmphoEnv) constructed to express amphotropic
murine leukemia vNirus (A-MLV) envelope protein as described in
U.S. Pat. No. 5,837,404 and (Petropoulos et al., 2000). The
pAmphoEnv vector uses the immediate early gene promoter of human
cytomegalovirus (CMV) and the SV40 polyadenlyation signal sequence
to produce A-MLV envelope mRNA in transfected cells. The pAmphoEnv
plasmid is modified by deleting the A-MLV envelope gene and
introducing restriction enzyme cleavage sites that can enable the
insertion of viral envelope fragments derived from a variety of
isolates, such as HIV-1. In the case of, HIV-1, the envelope open
reading frame spans approximately 2,600 nucleotides and encodes the
envelope polyprotein, gp160. The gp160 polyprotein is cleaved by a
cellular furin-like protease to produce two subunits, gp41 and
gp120. HIV-1 envelope expression vectors can be constructed in
stages as follows:
[0143] (a) Replacing the A-MLV Envelope Nucleic Acid Sequences from
the Envelope Expression Vector (pAmphoEnv) with a Multiple Cloning
Site Polylinker:
[0144] The A-MLV envelope nucleic acid sequences an be deleted from
the pAmphoEnv vector by restriction enzyme digestion. The digested
vector can be re-circularized by ligation to a duplex
oligonucleotide polylinker containing four unique internal
restriction sites (a, b, c, d) for insertion of envelope sequences.
The ligation reaction can be used to transform Escherichia Coli and
molecular clones containing the correct polylinker sequence can be
identified and confirmed by restriction mapping and DNA sequencing,
respectively. The introduction of multiple unique cloning sites
into the vector can facilitate the insertion of HIV-1 envelope
sequences. Restriction sites within the polylinker can be chosen
based on their infrequent occurrence in HIV-1 envelope sequences
(LANL HIV-1 database. www.lanl.gov). This vector can be referred to
as pCX. The functionality of the pCX vector can be demonstrated by
inserting a reporter gene or indicator nucleic acid, such as
firefly luciferase, into the pCX multiple cloning size and
measuring a signal from the indicator nucleic acid or reporter gene
activity in transfected cells. As used herein, "indicator nucleic
acid" refers to a nucleic acid encoding a protein, DNA or RNA
structure that either directly or through a reaction gives rise to
a measurable or noticeable signal, e.g. color or light of
measurable wavelength, or generation of a specific DNA or RNA
structure used as an indicator which could be amplified using any
one of a number of quantitative amplification assays.
[0145] (b) Inserting Viral Envelope Sequences into the pCX Envelope
Expression Vector:
[0146] Using mutagenic primers for PCR amplification, viral
envelope fragments are generated that contain two unique
restriction sites (a, b and c, d, respectively) adjacent to the
initiation and termination codons of, for example, the HIV-1
envelope open reading frame. Introduction of two unique restriction
sites at each end of the envelope open reading frame can improve
chances of cloning HIV-1 envelope fragments harboring internal
restriction sites for any one of the enzymes found in the multiple
cloning site of the pCX vector.
[0147] In the case of HIV-1, two well-characterized molecular
clones of HIV-1 with known differences in the envelope gene, NL4-3
(a syncytium-inducing, T-cell tropic, laboratory strain) and JR-CSF
(a non-syncytium-inducing, macrophage-tropic, primary isolate) can
be used as template for PCR amplification. The 2,600 nucleotide
amplification products can be digested with two restriction enzymes
(each enzyme cleaving at one end of the fragment; e.g. a and c or b
and d) and subsequently inserted into the pCX vector by ligation
and transformation of Escherichia Coli. Molecular clones containing
the appropriate envelope sequences can be identified by restriction
mapping and confirmed by DNA sequencing. The resulting plasmids,
pHIVenv (NL4-3) and pHIVenv (JR-CSF), can be used to express HIV-1
envelope proteins in transfected cells (FIG. 1A). The functionality
of the envelope expression vectors, such as the pHIVenv vectors,
can be demonstrated by measuring viral envelope synthesis in
transfected cells (Western Blot), and by their ability to
pseudotype envelope deficient retrovirus vectors. High titer virus
stocks using the human embryonic kidney 293 cell line has been
demonstrated (Petropoulos et al., 2000), however the present
invention is not restricted to those cell lines. Other suitable
cell lines used as a first cell for transfection of nucleic acid
obtained from the patient encoding a viral envelope protein
include, by way an example and not as limitation to the present
invention, 5.25; HOX; U87; MT2; PM1; CEM; etc. The cell line
optimally will be engineered to express one or more
co-receptors.
[0148] (c) Modifying the pCX Vector to Improve the Efficiency of
Cloning Viral Envelope Sequences:
[0149] To improve the cloning efficiency of viral envelope
fragments, the pCX expression vector can be modified by inserting a
bacterial killer gene cassette (e.g. control of cell death b gene
(ccdB) or a member of the hok-killer gene family) under the control
of the Escherichia Coli lac promoter into the multiple cloning site
(the et al., 1990; Bernard and Couturier, 1992; Bernard et al.,
1993). This modified vector is referred to as pCXccdB.
Transcription of the ccdB killer gene is repressed in bacterial
strains that express the laci.sup.q repressor, such as JM109. This
on an equivalent strain can be used to propagate plasmids carrying
the ccdB killer gene that are under the control of the lac
promoter. Conversely, in this system bacterial strains what do not
overexpress the laci.sup.q repressor, such as DH5 and Top10, cannot
maintain plasmids that express the ccdB gene. Transformants can be
killed due to the ccdB activity. DH5 and Top10 cells can be
purchased from several vendors (Life Technologies or Invitrogen).
Using this selective cloning approach, the parental expression
vector is propagated in a laci.sup.q bacterial strain. The vector
is digested with two restriction enzymes that both remove the ccdB
gene cassette, and, in the case of HIV-1, are compatible with the
insertion of HIV-1 envelope sequences (a, b, c, d). Following
ligation of the vector and envelope fragments, a strain of bacteria
lacking laci.sup.q is transformed. Once transformed, bacteria
containing plasmids in which the viral envelope inserts have
replaced the ccdB killer gene can grow. Bacteria containing
plasmids that retain or reconstitute the ccdB killer gene can not
survive. In this way, the population of transformed bacteria is
enriched for plasmids that contain viral envelope inserts, but is
lacking in the parental vector containing the ccdB gene. The
construction of the pCXccdB vector is not essential for the success
of phase I of this project, but it is expected to significantly
improve the efficiency of cloning HIV-1 envelope sequences derived
from patient samples; thus, the probability of maintaining the
heterogeneity of viral sequences can be improved. The structure of
the pCXccdB vector can be confirmed by restriction mapping and DNA
sequencing.
[0150] (d) Inserting Viral Envelope Sequences into the pCXccdB
Expression Vector:
[0151] The functionality of the pCXccdB vector can be evaluated by
setting up ligation reactions containing viral envelope sequences
and incompletely digested pCXccdB vector DNA. Following bacterial
transformation, plasmid DNA can be prepared from individual
bacterial clones and analyzed by restriction digestion for the
presence of viral envelope fragments and the absence of ccdB
sequences. The feasibility of this approach is tested by amplifying
the envelope region from a total of 13 available HIV-1 clones
(pCRII-91US005.11, pCRII-91006.10, pCRII-92US657.1,
pCRII-92US711.14, pCRII-91US712.4, pCRII-92US714.1,
pCRII-91HT652.11, pCRII-92BR020.4, pCRII-91HT651.1A,
pCRII-92HT593.1, pCRII-92HT594.10, pCRII-92HT596.4,
pCRII-92HT599.24), obtainable through the AIDS research reagent
reference program (ARRRP), Rockville, Md. Each fragment can be
inserted into pCXccdB and the structure of the resulting pHIVenv
expression vectors can be confirmed by restriction mapping and/or
DNA sequencing. The functionality of each pHIVenv vector can be
demonstrated by measuring HIV-1 envelope protein synthesis in
transfected cells (Western Blot), and by their ability to
pseudotype envelope-deficient retrovirus vectors.
[0152] 2) Construction of a Bio-safe Viral Expression Vector
Comprising Indicator Nucleic Acid in Place of the Region Encoding
the Envelope Protein.
[0153] A bio-safe viral vector is constructed to evaluate
inhibitors of viral entry according to similar means and methods as
described in U.S. Pat. No. 5,837,464 and Petropoulos et al., 2000
used to evaluate inhibitors of PR and RT. The viral expression
vector of the present invention can be co-transfected into cells,
together with the envelope expression vectors (described above) to
produce high titer virus stocks. Such virus stocks can be evaluated
for susceptibility to inhibitors of virus entry, including
antiviral drugs and neutralizing antibodies. In the case of HIV-1,
the viral expression vector can be generated from NL4-3, a
well-characterized infectious molecular clone of HIV-1. The 5' long
terminal repeat (LTR) which controls viral gene expression can be
modified so that transcription of the viral genes in transfected
cells is driven by the CMV immediate early promoter (Naviaux et
al., 1996). Most of the envelope gene can be deleted, but important
control elements such as the rev responsive element (RRE) and
accessory protein coding regions (rev, tat) are retained. In place
of the deleted envelope sequences, an indicator nucleic acid, such
as a firefly luciferase reporter gene cassette that is under the
control of CMV promoter-enhancer sequences (FIGS. 1B and 3) is
inserted. Virus infection can be monitored by measuring luciferase
activity in infected cells. It is conceivable, although unlikely,
that inter-plasmid recombination between the retroviral vector and,
for example, the pHIVenv sequences in transfected cells may lead to
the generation of infectious HIV-1. In effort to generate a biosafe
vector, introduction of several genetic alterations in the HIV
genome can be done. For example, deletion of most of the envelope
gene, while retaining the important control sequence, RRE, and also
deletion of the transcriptional enhancer sequences in the U3 region
of the 3' LTR of the vector (FIG. 2) can be accomplished. During
the replication of the retroviral genome, the U3 region located at
the 3' end of the virus genome serves as the template for the U3
region of the 5' LTR of the provirus in infected cells. Such
proviruses lack the strong promoter element in the U3 region of the
5' LTR and thus are unable to produce retroviral RNA in infected
cells. This self-inactivating (SIN) strategy has been used
successfully for several retroviral vector systems, including HIV-1
(Hwang et al., 1997; Miyoshi et al, 1998). In the assay of the
present invention, viral gene expression is not required in
infected cells because virus infection is measured by a detectable
signal produced by the indicator nucleic acid, such as the
production of luciferase activity, driven by its own separate
promoter (FIG. 1B). Deletion of envelope sequences and the
transcriptional enhancer region (U3) can be accomplished by
standard molecular cloning procedures, and each deletion can be
verified by DNA sequence analysis. Functionality of this vector,
for example in the case of HIV-1, designated pHIVlucAU3, can be
demonstrated by co-transfection of 293 cells with the pHIVenv
vector described above. Efficient transcomplementation of viral
proteins produced by both vectors in the transfected cells can lead
to the production of viral particles. Virus particles can be
harvested from the culture supernatants and analyzed by
Western-blotting. Virus titers can be quantitated by routine
applications of either p24 ELISA, quantitative PCR or TaqMan
assays.
[0154] It is not necessary to produce a self-inactivating viral
expression vector to carry out the present invention, but it is
desirable to improve assay reproducibility and biosafety.
[0155] 3) Identification of Suitable Cell Lines Which Express
Receptors and Co-receptors and Support Viral Infection.
[0156] Different mammalian cell lines that have been described
previously and are known to support infection of a particular virus
can be evaluated. As discussed herein for one embodiment relating
to HIV-1, the assay can be performed by (a) co-transfecting a first
cell with pHIVenv and pHIVlucU3, (b) harvesting virus after
transfection, (c) using this virus to infect a second cell, both in
the presence and absence of virus entry inhibitors, and (d)
measuring luciferase production in infected cells.
[0157] Table 1 lists representative examples of such cell lines
evaluated for HIV-1 infection, including the cell line and its
associated receptor/co-receptor. Several of these cell lines can be
obtained from public cell repositories.
[0158] Viral particles harvested from transfected 293 cell cultures
can be used to infect a variety of different cell lines. In the
case of HIV-1, the pHIVlucAU3 vector contains deletions in the
envelope gene and the U3 promoter-enhancer as described above,
therefore infection of a permissive cell line with virus particles
produced by this vector is restricted to a single round of
replication. This includes (a) virus attachment and entry, mediated
by the viral envelope proteins, produced in trans by the pHIVenv
vector as described, (b) the conversion of single stranded viral
RNA into double stranded DNA by RT, and (c) integration of viral
DNA into the host cell genome (provirus formation). The active
transcription of viral genes by RNA polymerase II that normally
occurs in infected cells following proviral integration can be
restricted by deleting essential viral promoter-enhancer sequences
in the pHIVlucAU3 vector. However, this restriction can not
interfere with luciferase gene expression in infected cells since
this gene is driven independently of viral gene expression using an
internal CMV promoter (FIG. 1B). The amount of luciferase activity
produced following infection can be used as a measure of viral
infectivity.
[0159] HIV-1 attachment and entry into host cells requires
interaction with a primary receptor (CD4) and one of several
co-receptors, most often CCR5 or CXCA4. Cell lines can be screened
that are known to express various combinations of CD4, CCR5 and
CXCR4. Specifically, cell lines listed in Table 1 that express (a)
CD4 plus CCR5, (b) CD4 plus CXCR4, and (c) CD4 plus CCR5 plus CXCR4
are evaluated. Cell lines that express the CD4 receptor alone, or
either the CCR5 or CXCR4 co-receptor alone, may serve as useful
controls and can be used to evaluate HIV-1 isolates that do not
require CD4 binding or that use co-receptors other than CCR5 and
CXCR4. The principal criterion for judging cell line suitability
can be infectivity as measured by luciferase production
(10.sup.4-10.sup.6 relative light units). In addition, cell lines
can be evaluated based on growth rates, viability, stability and
other parameters as deemed necessary. Cell lines can be selected
that are easy to maintain and for example, produce large amounts of
luciferase activity following infection, which can be infected by
different envelope receptor tropisms, e.g. CD4/CXCR4 and CD4/CCR5.
Additional well-characterized cell lines that support, for example,
HIV replication and express the HIV-1 receptor and co-receptors
(e.g. CEM-NKr-CCR5; release category a) are available through
public repositories such as the ARRRP.
[0160] Further, cell lines can be enhanced using standard
procedures, such as promoting infection by the addition of
polybrene to cells (Porter et al., 1998). For example, in the case
of HIV, other potential cell lines can be identified for use with
the present invention by infection with HIV-1 laboratory strains
and comparing the recombinant virus infectivity titers to those
obtained with infectious HIV-1, or by transfecting cells directly
with the viral expression plasmids described herein, and scoring
for virus production. Accumulation of viral transcripts can be
checked by using a quantitative RT-PCR assay. Cell lines suitable
for other viruses can be identified in a similar manner.
[0161] The present invention can optimize assay conditions and
allow for high-throughput testing of patient samples using
automation. Sample preparation methods can be optimized to
efficiently capture viral genomic and envelope RNTAS. RT-PCR
conditions can be optimized to enable amplification of
patient-derived viral envelope sequences, such as HIV-1 envelope
sequences (.about.2,600 base pairs) at low viral loads (.about.500
copies per ml).
[0162] 4) Demonstration of the Utility of the Assay
[0163] The utility of the assay of the present invention is
demonstrated by the results achieved from: (1) testing for
dose-dependent inhibition of viral entry in the presence of
well-characterized inhibitors; and the (2) testing for
dose-dependent inhibition of infection in the presence of
well-characterized HIV-1 neutralizing antibodies.
[0164] The following applications for the virus entry assay of the
present invention were evaluated:
[0165] i) detecting inhibition of HIV-1 replication by inhibitors
of virus attachment and entry (including fusion, receptor and
co-receptor inhibitors);
[0166] ii) measuring changes in susceptibility to HIV-1 attachment
and entry inhibitors; and
[0167] iii) detecting neutralization activity of
antibodies-generated in response to vaccines targeted against HIV-1
envelope proteins.
[0168] In a preferred embodiment, the assay can be performed by (a)
co-transfecting a first cell with pHIVenv and pHIVlucU3 vectors,
(b) harvesting virus after approximately 48 h after transfection,
(c) using this virus to infect a second cell, both in the presence
and absence of virus entry inhibitors and (d) measuring luciferase
production approximately 48-72 hrs. after infection. Dose-dependent
inhibition of HIV-1 replication can be evaluated against a wide
range of virus entry inhibitor concentrations using a 96-well
format. The appropriate concentration range can be determined
empirically for each inhibitor. The data can be plotted as the
percent inhibition of luciferase activity vs. drug concentration
(log.sub.10). Data analysis can be performed using computer
software. Inhibition curves are used to determine 50% inhibitory
concentrations (IC.sub.50) for specific drugs or antibodies (FIG.
6).
[0169] Envelope proteins derived from a variety of
well-characterized HIV-1 isolates are evaluated using pHIVenv
vectors constructed as described above. To define envelope
co-receptor tropism, in the case of HIV-1, infection using cells
expressing CD4 plus CXCR4 and CD4 plus CCR5 is evaluated as
described above. A wide variety of Compounds that are known to
inhibit HIV-1 entry (Table 2), including non-specific agents such
as sulfonated polyanions (dextran sulfate and heparin) can be used
with the assay of the present invention. Chemokines such as Rantes
and SDF-1, the natural ligands for the CCR5 and CXCR4 chemokine
receptors, respectively (see Alkhatib et al., 1996; Bleul et al.,
1996) are also suitable for use with the present invention.
Further, virus entry inhibitors such as T-20 and T1249 (Trimeris,
Inc.), PRO 542 (Progenics), 5a8 (Tanox) were used to evaluate
utility of the assay of the present invention.
[0170] Drug toxicity in target cells are evaluated using standard
viability or cytotoxicity assays (e.g. dye exclusion, MTS ATP).
[0171] HIV-1 mutants exhibiting reduced susceptibility to the
fusion inhibitor T20 (Rimsky et al., 1998) and the genetic
determinants (mutations) that enable these viruses to replicate in
the presence of drug map within the envelope protein (gp41-TM) have
been described. To demonstrate that the assay of the present
invention is capable of measuring changes in drug susceptibility
(i.e. resistance), (a) pHIVenv vectors are generated that carry
these mutant envelope genes, (b) first cells are co-transfected
using these vectors and the pHIVlucU3 vector, (c) viruses bearing
these mutant envelope proteins are harvested, and (d) the viruses
are tested for infectivity in the presence of T20. Reduced drug
susceptibility to T20 is evaluated by comparing the IC.sub.50 of
viruses bearing mutant envelope proteins to those that lack the
defined drug resistance mutations. Viruses bearing envelope
proteins with drug resistance mutations can exhibit higher
IC.sub.51 values than viruses bearing envelope proteins that lack
drug resistance mutations, i.e. inhibition can require a higher
drug concentration (equivalent to data presented in FIG. 8). Drug
resistance mutations can be introduced into envelope expression
vectors (pHIVenv) using standard site directed mutagenesis
techniques according to standard protocols (Petropoulos et al.,
2000; Ziermann et al., 2000)
[0172] It is widely accepted that effective vaccines that protect
against HIV-1 infection should elicit a strong humoral immune
response characterized by broadly cross-reactive neutralizing
antibodies. Consequently, the serum of vaccinated individuals is
routinely evaluated for the presence of high titer
neutralizing-antibodies targeted against the immunsogen. Most
recently, using the HIV-1/simian immunodeficiency virus (SIV)
chimeric virus macaque model (SHIV), Mascola and colleagues have
shown that passive transfer of such neutralizing antibodies led to
reduced viral load after mucosal challenge (Mascola et al., 2000).
The assay of the present invention can be used to rapidly and
reliably determine the viral neutralizing activity of antibodies
generated in response to vaccines targeting envelope antigens, such
HIV-1 envelope antigens. For example, the assay of the present
invention can (a) generate pHIVenv vectors that express a variety
of well-characterized envelope proteins, (b) co-transfect a first
cell using these vectors and the pHIVlucU3 vector, (c) harvest
viruses and incubate with serial dilucions of antibody preparations
or vaccine serum (d) test these viruses for infectivity in a second
cell. Data analysis and IC.sub.50 determinations can be performed
as described previously and in the literature. In the case of
HIV-1, viruses can be selected to represent different HIV-1 genetic
backgrounds (e.g. lade A, B, C, D, E, F), different cell and
co-receptor tropisms (macrophage/CCR5, T-cell/CXCR4), and different
envelope properties (syncytium and non-syncytium inducing,
laboratory adapted growth or primary isolate) (Table 2). It can be
beneficial to prepare stocks of a defined titer from each virus to
optimize assay sensitivity and reproducibility by using a virus
input of approximately 20-100 TCID.sub.50/well and making
adjustments as necessary. Antibody preparations can be selected
based on previously documented neutralization properties, either
functional, such as their ability to neutralize primary isolates,
or physical, such as their ability to bind specific gp120 or
gp41epitopes (Table 2). The performance of the assay of the present
invention can be judged against the activity of these
well-characterized antibody reagents in conventional virus
neutralization assays as described in the scientific literature.
Serum from a broadly representative group of HIV-1 infected
individuals can be used to establish an appropriate range of serum
dilutions that can maximize assay sensitivity, yet minimize
cytotoxicity. Cytoxicity can be evaluated using standard viability
or cytotoxicity assays (e.g. dye exclusion, MTS, ATP).
[0173] The following examples are presented to further illustrate
and explain the present invention and should not he taken as
limiting in any regard.
EXAMPLE 1
[0174] Measuring Phenotypic Drug Susceptibility to Inhibitors of
HIV-1 Entry
[0175] This example provides a means and method for accurately and
reproducibly measuring susceptibility to inhibitors of HIV-1
attachment and entry (heretofore collectively referred to as
entry). Based on this example, the means and method for measuring
susceptibility to inhibitors of HIV-1 entry can be adapted to other
viruses, including, but not limited to other lentiviruses (e.g.
HIV-2), other retroviruses (e.g. HTLV-1 and 2), hepadnaviruses
(human hepatitis B virus), flaviviruses (human hepatitis C virus)
and herpesviruses (human cytomegalovirus). This example further
provides a means and method for measuring alterations (increases
and decreases) in susceptibility to entry inhibitors.
[0176] Measurements of entry inhibitor susceptibility are carried
out using adaptations of the means and methods for phenotypic drug
susceptibility and resistance tests described in U.S. Pat. No.
5,837,464 (International Publication Number WO 97/27319) which is
hereby incorporated by reference.
[0177] One vector, an example of the envelope expression vector,
(pHIVenv) is designed to express the envelope polyprotein (gp160)
encoded by patient derived HIV envelope sequences (FIG. 1). Gp160
is subsequently cleaved by a cellular protease to generate the
surface (gp120SU) and transmembrane (gp41TM) subunits that comprise
the envelope protein on the surface of HIV-1 virus particles. A
second vector, an example of the viral expression vector, (either
pHIVluc or pHIVluc U3) is designed to express genomic and
subgenomic viral RNAs and all HIV proteins except the envelope
polyprotein (FIGS. 1A-1B).
[0178] In this application, patient-derived segment(s) correspond
to the coding region (.about.2.5 kB) of the HIV-1 envelope
polyprotein (gp160) and represent either (a) envelope sequences
amplified by the reverse transcription-polymerase chain reaction
method (RT-PCR) using viral RNA isolated from virus derived from
HIV-infected individuals, or (b) envelope sequences derived from
molecular clones of HIV-1 that contain specific mutations
introduced by site directed mutagenesis of a parental molecular
clone (typically NL4-3).
[0179] Isolation of viral RNA was performed using standard
procedures (e.g. RNAgents Total RNA Isolation System, Promega,
Madison Wis. or RNAzol, Tel-Test, Friendswood, Tex.). The RT-PCR
protocol was divided into two steps. A retroviral reverse
transcriptase [e.g. Superscript II (Invitrogen, Life Technologies)
Moloncay MuLV reverse transcriptase (Roche Molecular Systems, Inc.,
Branchburg, N.J.), or avian myeloblastosis virus (AMV) reverse
transcriptase, (Boehringer Mannheim, Indianapolis, Ind.)] was used
to copy viral RNA into first strand cDNA. The cDNA was then
amplified to high copy number using a thermostable DNA polymerase
[e.g. Taq (Roche Molecular Systems, Inc., Branchburg, N.J.), Tth
(Roche Molecular Systems, Inc., Branchburg, N.J.), PrimeZyme
(isolated from Thermus brockianus, Biometra, Gottingen, Germany)]
or a combination of thermostable polymerases as described for the
performance of "long PCR" (Barnes, W. M., (1994) Proc. Natl. Acad.
Sci, USA 91, 2216-2220) [e.g. Expand High Fidelity PCR System
(Taq+Pwo), (Boehringer Mannheim. Indianapolis, Ind.) OR GeneAmp XL
PCR kit (Tth+Vent), (Roche Molecular Systems, Inc., Branchburg,
N.J.), Advantage-2, (CloneTech).
[0180] Oligo-dT was used for reverse transcription of viral RNA
into first strand cDNA. Envelope PCR primers, forward primer
Xho/Pin and reverse primer Mlu/Xba (Table 3) were used to amplify
the patient-derived segments. These primers are designed to amplify
the .about.2.5 kB envelope gene encoding the gp160 envelope
polyprotein, while introducing Xho I and Pin AI recognition sites
at the 5' end of the PCR amplification product, and Mlu I and Xba I
sites at the 3' end of the PCR amplification product.
[0181] Patient derived segments (2.5 kB envelope sequence
amplification product) were inserted into HIV-1 envelope expression
vectors using restriction endonuclease digestion, DNA ligation and
bacterial transformation methods as described in U.S. Pat. No.
5,837,464 (International Publication Number WO 97/27319), with
minor adaptations. The .about.2.5 kB amplification product was
digested with either Xho I or Pin AI at the 5' end and either Mlu I
or Xba I at the 3' end. The resulting digestion products were
ligated, using DNA ligase, into the 5' Xho I/Pin AI and 3' Mlu
I/Xba I sites of modified pCXAS or pCXAT expression vectors. The
construction of the pCXAS and pCXAT vectors has been described (in
the CPT of base patent, I believe it was example 6 U.S. Pat. No.
5,837,464 (International Publication Number WO 97/27319)). Modified
pCXAS and pCXAT vectors contain a Pin AI restriction site in
addition to the Xho I, Mlu I and Xba I restriction sites that exist
in pCXAS and PCXAT. The Pin AI site was introduced between the Xho
I and Mlu I sites by site directed mutagenesis, such that the four
sites are located 5' to 3' in the following order; Xho I, Pin AI,
Mlu I and Xba I. In a preferred embodiment, the 2.5 kB
amplification products were digested with Pin AI and Mlu I and
ligated into the 5' Pin AI site and the 3' Mlu I site of the
modified pCXAS expression vector. Ligation reaction products were
used to transform E. coli. Following a 24-36 h incubation period at
30-37.degree. C., the expression vector plasmid DNA was purified
from the E. coli cultures. To ensure that expression vector
preparations adequately represents the HIV quasi-species present in
the serum of a given patient, many (>100) independent E. coli
transformants were pooled and used for the preparations of pHIVenv
plasmid DNA. Vectors that are assembled in this manner for the
purposes of expressing patient virus derived envelope proteins are
collectively referred to as pHIVenv (FIGS. 1 and 3).
[0182] The genomic HIV expression vectors pHIVluc and pHIVluc@U3
are designed to transcribe HIV genomic RNA and subgenomic mRNAs and
to express all HIV proteins except the envelope polyprotein (FIG.
1B). In these vectors, a portion of the envelope gene has been
deleted to accommodate a functional indicator gene cassette, in
this case, "Firefly Luciferase" that is used to monitor the ability
of the virus to replicate in the presence or absence of anti-viral
drugs. In pHIVluc@U3, a portion of the 3' U3 region has been
deleted to prevent transcription of viral RNAs from the 5' LTR in
infected cells.
[0183] Susceptibility assays for HIV-1 entry inhibitors were
performed using packaging host cells consisting of the human
embryonic kidney cell line 293 (Cell Culture Facility, UC San
Francisco, SF, CA) and target host cells consisting of a human
osteosarcoma (HOS) cell line expressing CD4 (HT4) plus CCR5, and
CXCR4, or astrocytoma (U-87) cell lines expressing either CD4 and
CCR5 or CD4 and CXCR4.
[0184] Drug susceptibility testing was performed using pHIVenv and
pHIVluc or pHIVluc U3. Pseudotyped HIV particles containing
envelope proteins encoded by the patient derived segment were
produced by transfecting a packaging host cell (HEK 293) with
resistance test vector DNA. Virus particles were collected
(.about.48 h) after transfection and are used to infect target
cells (HT4/CCR5/CXCR4, or U-87/CD4/CXCR4, or U-87/CD4,/CCR5) that
express HIV receptors (i.e. CD4) and co-receptors (i.e. CXCR4,
CCR5). After infection (.about.72 h) the target cells are lysed and
luciferase activity is measured. HIV must complete one round of
replication to successfully infect the target host cell and produce
luciferase activity. The amount of luciferase activity detected in
the infected cells is used as a direct measure of "infectivity"
(FIGS. 1 and 2). If for any reason (e.g. lack of the appropriate
receptor or co-receptor, inhibitory drug activity, neutralizing
antibody binding), the virus is unable to enter the target cell,
luciferase activity is diminished. Drug susceptibility is assessed
by comparing the infectivity in the absence of drug to infectivity
in the presence of drug. Relative drug susceptibility can be
quantified by comparing the susceptibility of the "test" virus to
the susceptibility of a well-characterized reference virus
(wildtype) derived from a molecular clone of HIV-1, for example
NL4-3 or HXB2.
[0185] Packaging host cells were seeded in 10-cm-diameter dishes
and were transfected one day after plating with pHIVenv and pHIVluc
or pHIVlucU3. Transfections were performed using a
calcium-phosphate co-precipitation procedure. The cell culture
media containing the DNA precipitate was replaced with fresh
medium, from one to 24 hours, after transfection. Cell culture
media containing viral particles was typically harvested 2 days
after transfection and was passed through a 0.45-mm filter. Before
infection, target cells were plated in cell culture media. Entry
inhibitor drugs were typically added to target cells at the time of
infection (one day prior to infection on occasion). Typically, 3
days after infection target cells were assayed for luciferase
activity using the Steady-Glo reagent (Promega) and a
luminometer.
[0186] In one embodiment, the susceptibility to a fusion inhibitor
drug (T-20, also referred to as DP178; Trimeris, Research Triangle
Park, N.C.) was demonstrated (FIG. 6). Target cells
(HT4/CCR5/CXCR4) expressing CD4, CCR5 and CXCR4 were infected in
the absence of T-20 and over a wide range of T-20 concentrations
(x-axis log.sub.10 scale). The percent inhibition of viral
replication (y-axis) was determined by comparing the amount of
luciferase produced in infected cells in the presence of T-20 to
the amount of luciferase produced in the absence of T-20. R5 tropic
(JRCSF, 91US005.11), X4 tropic (NL4-3, 92HT599.24) and dual tropic
(92HT593.1) viruses were tested. Drug susceptibility is quantified
by determining the concentration of T-20 required to inhibit viral
replication by 50% (IC.sub.50, shown as vertical dashed lines in
FIG. 6). Viruses with lower IC.sub.50 values are more susceptible
to T-20 than viruses with higher IC50 values.
[0187] In still further embodiments, susceptibility to a wide
variety of entry inhibitors can be measured. These inhibitors
include, but are not limited to, the drugs and compound listed in
Table 4 (anti-HIV drug table).
[0188] In a second embodiment, susceptibility to a CCR5 inhibitor
belonging to the 4-(piperidin-1-yl) butane class of compounds
(Dorn, C. P. et al., (2001), Finke, P. E. et al. , (2001); Merck,
West Point, Pa.) is demonstrated. Target cells (U-87/CD4/CCR5)
expressing CD4 and CCR5 (R5 cells) were infected in the absence of
the CCR5 inhibitor and over a wide range of CCR5 inhibitor
concentrations (x-axis log.sub.10 scale). The percent inhibition of
viral replication (y-axis) was determined by comparing the amount
of luciferase produced in infected cells in the presence of CCR5
inhibitor to the amount of luciferase produced in the absence of
CCR5 inhibitor. R5 tropic (JRCSF), X4 tropic (NL4-3) and dual
tropic viruses (92HT593.1) were tested. Drug susceptibility was
quantified by determining the concentration of CCR5 inhibitor
required to viral replication by 50% (IC.sub.50, shown as vertical
dashed lines in FIG. 8). Viruses with lower IC.sub.50 values are
more susceptible to the CCR5 inhibitor than viruses with higher
IC.sub.50 values. The X4 tropic virus did not infect the
U-87/CD4/CCR5 target cells.
[0189] In a third embodiment, susceptibility to a CXCR4 inhibitor
(AMD3100; AnorMED) was demonstrated. Target cells (U-87/CD4/CXCR4)
expressing CD4 and CXCR4 were infected in the absence of the CXCR4
inhibitor and over a wide range of CXCR4 inhibitor concentrations
(x-axis log.sub.10 scale) The percent inhibition of viral
replication (y-axis) was determined by comparing the amount of
luciferase produced in infected cells in the presence of CXCR4
inhibitor to the amount of luciferase produced in the absence of
CXCR4 inhibitor. R5 tropic (JRCSF), X4 cropic (NL4-3) and dual
tropic (92HT593.1) viruses were tested. Drug susceptibility is
quantified by determining the concentration of CXCR4 inhibitor
required to inhibit viral replication by 50% (IC.sub.50, shown as
vertical dashed lines in FIG. 9). Viruses with lower IC.sub.50
values are more susceptible to the CCR5 inhibitor than viruses with
higher IC.sub.50 values. The R5 tropic virus did not infect the
U-87/CD4/CXCR4 target cells.
[0190] Susceptibility to a CD4 inhibitor (e.g. murine monoclonal
antibody 5A8; Tanox, Houston, Tex.) can be measured. Target cells
(e.g. HT4/CCR5/CXCR4, U-87/CD4/CXCR4, or TJ-87/CD4/CCR5) expressing
CD4 and one or both co-receptors can be infected in the absence of
the CD4 inhibitor drug and over a wide range of CD4 inhibitor drug
concentrations (x-axis log.sub.10 scale). The percent inhibition of
viral replication (y-axis) can be determined by comparing the
amount of luciferase produced in infected cells in the presence of
CD4 inhibitor to the amount of luciferase produced in the absence
of CD4 inhibitor. R5 tropic (e.g. JRCSF), X4 tropic (e.g. NL4-3)
and dual tropic (e.g. 92HT593.1) viruses can be tested. Drug
susceptibility can be quantified by determining the concentration
of CD4 inhibitor required to inhibit viral replication by 50%
(IC.sub.50). Viruses with lower IC.sub.50 values are more
susceptible to the CD4 inhibitor than viruses with higher IC.sub.50
values.
EXAMPLE 2
[0191] Discovery, Optimization and Characterization of New and
Novel Inhibitors of Virus Entry.
[0192] In one embodiment, the virus entry assay can be used to
identify new compounds/chemical entities that inhibit virus entry.
Target cells (e.g. HT4/CCR5/CXCR4, U-87/CD4/CXCR4, or
U-37/CD4/CCR5) expressing CD4 and one or both co-receptors can be
infected in the presence of individual members of large chemical
libraries (high throughput screening, HTS). The ability of a
compound to inhibit viral replication (a "hit") can be determined
by comparing the amount of luciferase produced in infected target
cells in the presence of a specific compound to the amount of
luciferase produced in the absence of the compound.
[0193] In a further embodiment, the virus entry assay can be used
to optimize the antiviral activity of lead compounds identified by
HTS. Chemical modified derivatives of lead compounds can be tested
to identify specific derivatives that have enhanced virus entry
inhibitory activity. Target cells (e.g. HT4/CCR5/CXCR4,
U-87/CD4/CXCR4, or U-87/CD4/CCR5) expressing CD4 and one or both
co-receptors can be infected in the absence of the inhibitor
candidate and over a wide range of inhibitor candidate
concentrations (x-axis log.sub.10 scale). The percent inhibition of
viral replication (y-axis) can be determined by comparing the
amount of luciferase produced in infected cells in the presence of
the candidate inhibitor to the amount of luciferase produced in the
absence of candidate inhibitor. Drug susceptibility can be
quantified by determining the concentration of inhibitor candidate
required to inhibit viral replication by 50% (IC.sub.50).
Derivatized compounds with lower IC.sub.50 values are more potent
inhibitors of virus entry (have greater antiviral activity) than
derivatives with higher IC.sub.50 values.
[0194] In yet a further embodiment, the virus entry assay can be
used to characterize the mechanism of action of new virus entry
inhibitor drug candidates, and the antiviral activity against a
spectrum of viruses that may differ in susceptibility. Target cells
(e.g. HT4/CCR5/CXCR4, U-87/CD4/CXCR4, or U-87/CD4/CCR5) expressing
CD4 and one or both co-receptors can be infected in the absence of
the new entry inhibitor drug candidate and over a wide range of
entry inhibitor drug concentrations (x-axis log.sub.10 scale). The
percent inhibition of viral replication (y-axis) can be determined
by comparing the amount of luciferase produced in infected cells in
the presence of new entry inhibitor to the amount of luciferase
produced in the absence of the new entry inhibitor. R5 tropic (e.g.
JRCSF), X4 tropic (e.g. NL4-3) and dual tropic (e.g. 92HT593.1)
viruses can be tested. Drug susceptibility can be quantified by
determining the concentration of CD4 inhibitor required to inhibit
viral replication by 50% (IC.sub.50).
[0195] To determine whether the new entry inhibitor acts by
blocking the CCR5 or CXCR4 co-receptors, the R5 tropic viruses are
tested against the new inhibitor in U-87/CD4/CCR5 cells and X4
tropic viruses are tested against the new inhibitor using
U-87/CD4/CXCR4 cells. Inhibition of R5 virus infection is
indicative of CCR5 co-receptor antagonism and conversely,
inhibition of X4 virus infection is indicative of CXCR4 co-receptor
antagonism. Inhibition of R5 and X4 virus infection may be
indicative of either CD4 antagonism or the inhibition of membrane
fusion.
[0196] To characterize the activity of a new inhibitor against
viruses that exhibit resistance, or have reduced susceptibility, to
other virus entry inhibitors of the same class, or different class,
selected panels of drug resistant viruses can be tested in the
virus entry assay using the new entry inhibitor drug. The panel may
include viruses with varying levels of susceptibility to CCR5
inhibitors, CXCR4 inhibitors, CD4 inhibitors, and membrane fusion
inhibitors. The panel may include viruses with one or more specific
mutations that are associated with reduced
susceptibility/resistance to one or more entry inhibitors.
EXAMPLE 3
[0197] Identifying Envelope Amino Acid Substitutions/Mutations that
Alter Susceptibility to Virus Entry Inhibitors.
[0198] This example provides a means and method for identifying
mutations in HIV-1 envelope that confer reduced
susceptibility/resistance to virus entry inhibitors. This example
also provides a means and method for quantifying the degree of
reduced susceptibility to entry inhibitors conferred by specific
envelope mutations.
[0199] Envelope sequences derived from patient samples, or
individual clones derived from patient samples, or envelope
sequences engineered by site directed mutagenesis to contain
specific mutations, are tested in the entry assay to quantify drug
susceptibility based on a well-characterized reference standard
(e.g. NL4-3, HXB2).
[0200] In one embodiment, susceptibility to longitudinal patient
samples (viruses collected from the same patient at different
timepoints) is evaluated. For example, susceptibility to entry
inhibitors is measured prior to initiating therapy, before or after
changes in drug treatment, or before or after changes in virologic
(RNA copy number), immunologic (CD4 T-cells), or clinical
(opportunistic infection) markers of disease progression.
[0201] Genotypic Analysis of Patient HIV Samples
[0202] Envelope sequences representing patient sample pools, or
clones derived from patient pools, can be analyzed by any broadly
available DNA sequencing methods. In one embodiment of the
invention, patient HIV sample sequences are determined using viral
RNA purification, RT/PCR and dideoxynucleotide chain terminator
sequencing chemistry and capillary gel electrophoresis (Applied
Biosystems, Foster City, Calif.). Envelope sequences of patient
virus pools or clones are compared to reference sequences, other
patient samples, or to a sample obtained from the same patient
prior to initiation of therapy, if available. The genotype is
examined for sequences that are different from the reference or
pre-treatment sequence and correlated to differences in entry
inhibitor susceptibility.
[0203] Entry Inhibitor Susceptibility of Site Directed Mutants
[0204] Genotypic changes that correlate with changes in fitness are
evaluated by constructing envelope expression vectors (pHIVenv)
containing the specific mutation on a defined, drug susceptible,
genetic background (e.g. NL4-3 reference strain). Mutations may be
incorporated alone and/or in combination with other mutations that
are thought to modulate the entry inhibitor susceptibility.
Envelope mutations are introduced into pHIVenv vectors using any of
the broadly available methods for site-directed mutagenesis. In one
embodiment of this invention the mega-primer PCR method for
site-directed mutagenesis is used (Sarkar, G. and Summer, S. S.,
1990). A pHIVenv vector containing a specific envelope mutation or
group of mutations are tested using the virus entry assay described
in Example 1. Drug susceptibility of the virus containing envelope
mutations is compared to the drug susceptibility of a genetically
defined drug susceptible virus that lacks the specific mutations
under evaluation. Observed changes in entry inhibitor
susceptibility are attributed to the specific mutations introduced
into the pHIVenv vector.
[0205] In one embodiment of the invention, reduced susceptibility
to the fusion inhibitor T-20 conferred by specific drug resistance
mutations in the gp41envelope protein is demonstrated (FIG. 7).
Cells expressing CD4, CCR5 and CXCR4 were infected in the absence
of T-20 and over a wide range of T-20 concentrations (x-axis
log.sub.10 scale). The percent inhibition of viral replication
(y-axis) was determined by comparing the amount of luciferase
produced in infected cells in the presence of T-20 to the amount of
luciferase produced in the absence of T-20. Isogenic viruses
containing one or two specific mutations in the gp41transmembrane
envelope protein were tested (highlighted in red in the figure
legend; Rimsky et al., J. Virol. 72: 986-993). Drug susceptibility
is quantified by determining the concentration of T-20 required to
inhibit viral replication by 50% (IC.sub.50, shown as vertical
dashed lines). Viruses with lower IC.sub.50 values are more
susceptible to T-20 than viruses with higher IC.sub.50 values.
[0206] In one embodiment, drug resistance mutations were introduced
into well-characterized X4 tropic (NL4-3) and R5 tropic (JRCSF)
viruses. T20 susceptibility was measured using the virus entry
assay (FIG. 7). The fold change (FC) in T-20 susceptibility for
each virus was determined by dividing the IC50 of the test virus by
the IC50 of the HXB2 strain of HIV-1. T-20 sensitivity of similar
mutant viruses has been reported in the scientific literature
(Rimsky et al.,). In this embodiment, viruses with one mutation
within the GIV motif of gp41(DIV, GIM, SIV) were less susceptible
to T20 than the wildtype virus (GIV) (FIG. 11). Viruses with two
mutations within the GIV motif (DIM, SIM, DTV) were less
susceptible to T20 than viruses with one, or no mutations in the
GIV motif (FIG. 11).
[0207] In another embodiment, mutations that may confer reduced (or
increased) susceptibility to the entry inhibitor are identified by
sequencing the envelope genes of the sensitive and resistant
viruses. The deduced amino acid sequences of the sensitive and
resistant viruses are compared to identify candidate drug
resistance mutations. The ability of a specific mutation to confer
altered drug susceptibility is confirmed or disproved by
introducing the mutation into a drug sensitive virus and measuring
the susceptibility of the mutant virus in the virus entry assay. In
the example represented here, a short stretch of amino acid
sequences within the first heptad repeat (HR-1) of the HIV-1
gp41transmembrane envelope protein is aligned for viruses
exhibiting different T-20 susceptibilities (FIG. 11). Highlighted
amino acids represent mutations known to confer reduced
susceptibility to T-20.
[0208] Similar phenotypic and genotypic analyses can be used to
identify envelope amino acid sequences that (a) alter/influence
susceptibility to CCR5 or CXCR4 inhibitors, (b) specify X4, R5 and
dual tropism, and (c) elicit neutralizing antibodies.
[0209] In one embodiment, reduced susceptibility to co-receptor
(CCR5, CXCR4) inhibitors conferred by specific envelope amino acid
sequences/mutations is demonstrated.
[0210] In a further embodiment, reduced susceptibility to receptor
(CD4) inhibitors conferred by specific envelope amino acid
sequences/mutations is demonstrated.
EXAMPLE 4
[0211] Determining HIV-1 Co-receptor and Receptor Tropism
[0212] This example provides a means and method for determining
HIV-1 co-receptor tropism. This example also provides a means and
method for determining HIV-1 receptor tropism.
[0213] In one embodiment, viruses that use the CCR5 co-receptor are
identified. In a related embodiment, viruses that use the CXCR4
co-receptor are identified. In a further related embodiment,
viruses that use CCR5 and CXCR4 are identified. In a further
related embodiment, viruses that use co-receptors other than CCR5
or CXCR4 are identified.
[0214] In another embodiment, viruses that use the CD4 receptor are
identified. In a related embodiment, viruses that use CD8 are
identified. In a further related embodiment, viruses that do not
require CD4 or CD8 to infect cells are identified.
[0215] In this embodiment, the assay is performed using two cell
lines. One cell line expresses CD4 plus CCR5 (U-87/CD4/CCR5), also
referred to as R5 cells in this application. The other cell line
expresses CD4 and CXCR4 (U-87/CD4/CXCR4) also referred to as X4
cells in this application. The virus entry assay is performed by
infecting individual cell cultures with recombinant virus stocks
derived from cells transfected with pHIVenv and pHIV luc or
pHIVlucDU3 vectors. pHIVenv vectors contain patient virus derived
sequences and express HIV-1 envelope proteins (gp120SU, gp41TM). In
this embodiment viruses are evaluated in using R5 and X4 target
cells cultured in 96 well plates (FIG. 3A). Typically, R5 and X4
cells are plated one day prior to infection. Infection with each
virus stock is performed in the absence of drug (no drug), in the
presence of inhibitory concentrations of a drug that preferentially
inhibits R5 tropic viruses (CCR inhibitor, e.g. a piperidin 1yl
butane compound), and in the presence of inhibitory concentrations
of a drug that preferentially inhibits X4 tropic viruses (CXCR4
inhibitor, e.g. AMD3100). Co-receptor tropism is assessed by
comparing the amount of luciferase activity produced in each cell
type, both in the presence and absence of drug. In this embodiment,
the results of the assay are interpreted by comparing the ability
of each virus to preferentially infect (produce luciferase
activity) R5 cells or X4 cells, or both X4 and R5 cells if the
virus is dual tropic. The ability of the CCR5 or CXCR4 inhibitor to
specifically block infection (inhibit luciferase activity) is also
evaluated (FIG. 3B). In this embodiment, X4 tropic viruses infect
X4 cells but not R5 cells and infection of X4 cells is blocked by
the the CXCR4 inhibitor (AMD3100). In this embodiment, R5 tropic
viruses infect R5 cells but not X4 cells and infection of R5 cells
is blocked by the CCR5 inhibitor (piperidin-1yl butane compound).
In this embodiment, dual tropic, or mixtures of X4 and R5 tropic
viruses, infect both X4 and R5 cells and infection of R5 cells is
blocked by the CCR5 inhibitor and infection of X4 cells is blocked
by the CXCR4 inhibitor. In this embodiment, non-viable viruses do
not replicate in either X4 or R5 cells (luciferase activity is not
produced).
[0216] In another embodiment, the assay is performed using three or
more cell lines. One cell line expresses CD4 plus CCR5
(U-87/CD4/CCR5), also referred to as R5 cells in this application.
The Ether cell line expresses CD4 and CXCR4 (U-87/CD4/CXCR4) also
referred to as X4 cells in this application. Additional cell lines
express CD4 plus other candidate HIV-1 co-receptors, including, but
not limited to, BONZO, BOB, etc. See Table 1. These additional cell
lines express other candidate co-receptors, but do not express CCR5
or CXCR4. The virus entry assay is performed by infecting
individual cell cultures with recombinant virus stocks derived from
cells transfected with pHIVenv and pHIV luc or pHIVlucDU3 vectors.
pHIVenv vectors contain patient virus derived sequences and express
HIV-1 envelope proteins (gp120SU, gp41TM). In this embodiment
viruses are evaluated in using cells cultured in 96 well plates.
Infection with each virus stock is performed in R5 cells, X4 cells
and the cell lines expressing CD4 plus the candidate co-receptors.
Co-receptor tropism is assessed by comparing the amount of
luciferase activity produced in each cell type. In this embodiment,
the results of the assay are interpreted by comparing the ability
of each virus to preferentially infect (produce luciferase
activity) R5 cells or X4 cells, or the cell line that expresses the
candidate co-receptor. In this embodiment, X4 tropic viruses infect
X4 cells but not R5 cells. In this embodiment, R5 tropic viruses
infect R5 cells but not X4 cells. In this embodiment dual tropic,
or mixtures of X4 and R5 tropic viruses, infect both X4 and R5
cells. In this embodiment, the infection of cell lines expressing
alternative candidate co-receptors (neither CCR5 or CXCR4) is
attributed to tropism for the alternative co-receptor. In this
embodiment, non-viable viruses do not replicate in either X4 or R5
cells.
[0217] In another embodiment, the assay is performed using four
cell lines. One cell line expresses CD4 plus CCR5 (U-87/CD4/CCR5),
also referred to as R5 cells in this application. A second other
cell line expresses CD4 and CXCR4 (U-87/CD4/CXCR4) also referred to
as X4 cells in this application. A third cell line expresses CD8
plus CCR5 (U-87/CD8/CCR5), also referred to as CD8/R5 cells in this
application. A fourth cell line expresses CD8 and CXCR4
(U-87/CD8/CXCR4) also referred to as CD8/X4 cells in this
application. The virus entry assay is performed by infecting
individual cell cultures with recombinant virus stocks derived from
cells transfected with pHIVenv and pHIV luc or pHIVlucDU3 vectors.
pHIVenv vectors contain patient virus derived sequences and express
HIV-1 envelope proteins (gp120SU, gp41TM). In this embodiment
viruses are evaluated in using cells cultured in 96 well plates.
Infection with each virus stock is performed in R5 cells, X4 cells,
CD8/R5 cells and CD8/X4 cells. Co-receptor tropism is assessed by
comparing the amount of luciferase activity produced in each cell
type. In this embodiment, the results of the assay are interpreted
by comparing the ability of each virus to preferentially infect
(produce luciferase activity) R5 cells, X4 cells, CD8/R5 cells, or
CD8/X4 cells. In this embodiment, CD4 tropic viruses infect X4
cells and/or R5 cells. In this embodiment, CD8 tropic viruses
infect CDS/R5 cells and/or CD8/X4 cells. In this embodiment, dual
tropic (CD4 and CD8 receptor use) viruses infect X4 cells and/or R5
cells plus CD8/X4 and/or CD8/R5 cells. In this embodiment, the
infection of cell lines expressing CD8 but not CD4 is attributed to
CD8 receptor tropism. In this embodiment, non-viable viruses do not
replicate in either X4 or R5 cells.
[0218] In a further related embodiment, the assay is performed
using two cell lines. One cell line expresses CD4 plus CCR5 and
CXCR4 (HT4/CCR5/CXCR4). A second cell line expresses CD8 plus CCR5
and CXCR4 (HOS/CD8/CCR5/CXCR4). The virus entry assay is performed
by infecting individual cell cultures with recombinant virus stocks
derived from cells transfected with pHIVenv and pHIV luc or
pHIVlucDU3 vectors. pHIVenv vectors contain patient virus derived
sequences and express HIV-1 envelope proteins (gp120SU, gp41TM). In
this embodiment viruses are evaluated in using cells cultured in 96
well plates. Infection with each virus stock is performed in
HT4/CCR5/CXCR4 cells and HOS/CD8/CCR5/CXCR4 cells. Co-receptor
tropism is assessed by comparing the amount of luciferase activity
produced in each cell type. In this embodiment, the results of the
assay are interpreted by comparing the ability of each virus to
preferentially infect (produce luciferase activity) HT4/CCR5/CXCR4
cells or HOS/CD8/CCR5/CXCR4 cells. In this embodiment, CD4 tropic
viruses infect HT4/CCR5/CXCR4 cells, but not HOS/CD8/CCR5/CXCR4
cells. In this embodiment, CD8 tropic viruses infect
HOS/CD8/CCR5/CXCR4 cells but not HT$/CCR5/CXCR4 cells. In this
embodiment, dual tropic (CD4 and CD8 receptor use) viruses infect
both HT4/CCR5/CXCR4 cells and HOS/CD8/CCR5/CXCR4 cells. In this
embodiment, the infection of cell lines expressing CD8 but not CD4
is attributed to CD8 receptor tropism. In this embodiment,
non-viable viruses do not replicate in either X4 or R5 cells.
[0219] In another embodiment, the assay is performed using two cell
lines. One cell line expresses CD4 plus CCR5 and CXCR4
(HT4/CCR5/CXCR4). A second cell line expresses CCR5 and CXCR4 but
not CD4 or CD8 (HOS/CCR5/CXCR4). The virus entry assay is performed
by infecting individual cell cultures with recombinant virus stocks
derived from cells transfected with pHIVenv and pHIV luc or
pHIVlucDU3 vectors. pHIVenv vectors contain patient virus derived
sequences and express HIV-1 envelope proteins (gp120SU, gp41TM). In
this embodiment viruses are evaluated in using cells cultured in 96
well plates. Infection with each virus stock is performed in
HT4/CCR5/CXCR4 cells and HOS/CCR5/CXCR4 cells. CD4 and CD8
independent infection is assessed by comparing the amount of
luciferase activity produced in each cell type. In this embodiment,
the results of the assay are interpreted by comparing the ability
of each virus to preferentially infect (produce luciferase
activity) HT4/CCR5/CXCR4 cells or HOS/CCR5/CXCR4 cells. In this
embodiment, CD4 dependent viruses infect HT4/CCR5/CXCR4 cells, but
not HOS/CCR5/CXCR4 cells. In this embodiment, CD4 independent
viruses infect both HOS/CCR5/CXCR4 cells and HT4/CCR5/CXCR4 cells.
In this embodiment, the infection of cell lines that lack CD4
expression is attributed to CD4 independent infection. In this
embodiment, non-viable viruses do not replicate in either X4 or R5
cells.
EXAMPLE 5
[0220] Identifying HIV-1 Envelope Amino Acid
Substitutions/Mutations that Alter Co-receptor and Receptor
Tropism
[0221] This example provides a means and method for identifying
HIV-1 envelope amino acid sequences that specify, or alter,
co-receptor tropism (X4 vs. R5 vs. dual X4/R5). This example also
provides a means and method for identifying HIV-1 envelope amino
acid sequences that specify co-receptor usage other than CXCR4 or
CCR5. The example also provides a means and method for identifying
HIV-1 envelope sequences that specific, or receptor tropism (CD4
vs. CD8).
[0222] Envelope sequences derived from patient samples, or
individual clones derived from patient samples, or envelope
sequences engineered by site directed mutagenesis to contain
specific mutations, are tested in the entry assay to determine
co-receptor tropism as described in Example 4.
[0223] In one embodiment, co-receptor tropism of longitudinal
patient samples (viruses collected from the same patient at
different timepoints) is evaluated. For example, co-receptor
tropism is evaluated prior to initiating therapy, before or after
changes in drug treatment, or before or after changes in virologic
(RNA copy number), immunologic (CD4 T-cells), or clinical
(opportunistic infection) markers of disease progression.
[0224] In another embodiment, co-receptor tropism is evaluated for
samples collected from a large number of different patients. In a
further embodiment, co-receptor tropism is evaluated for samples
collected from a large number of patients representing different
virus and patient populations. Such patient populations may
include, but are not limited to, newly infected patients,
chronically infected patients, patients with advanced disease, and
patients undergoing antiretroviral therapy or immuno-therapy. Such
virus populations may include, but are not limited to, viruses with
distinct genetic characteristics (clade A, B, C, D, E, F, G)
viruses susceptible to antiretroviral drugs, viruses with reduced
susceptibility/resistance to antiretroviral drugs.
[0225] Genotypic Analysis of Patient HIV Samples
[0226] Envelope sequences representing patient sample pools, or
clones derived from patient pools, can be analyzed by any broadly
available DNA sequencing methods. In one embodiment of the
invention, patient HIV sample sequences are determined using viral
RNA purification, RT/PCR and dideoxynucleotide chain terminator
sequencing chemistry and capillary gel electrophoresis (Applied
Biosystems, Foster City, Calif.). Envelope sequences of patient
virus pools or clones are compared to reference sequences, other
patient samples, or to a sample obtained from the same patient
prior to initiation of therapy, if available. The genotype is
examined for sequences that are different from the reference or
pre-treatment sequence and correlated to differences in entry
inhibitor susceptibility.
[0227] Co-Receptor and Receptor Tropism of Genetically
Characterized Viruses
[0228] Envelope amino acid sequences that correlate co-receptor
tropism are evaluated by constructing envelope expression vectors
(pHIVenv) containing a specific mutation on a defined genetic
background (e.g. NL4-3 for X4 tropism, JRCSF for R5 tropism).
Mutations may be incorporated alone and/or in combination with
other mutations that are thought to modulate (co-receptor usage.
Envelope mutations are introduced into pHIVenv vectors using any of
the broadly available methods for site-directed mutagenesis. In one
embodiment of this invention the mega-primer PCR method for
site-directed mutagenesis is used (Sarkar, G. and Summer, S. S.,
1990). A pHIVenv vector containing a specific envelope mutation or
group of mutations are tested using the virus entry assay described
in Example 1. Co-receptor tropism of the virus containing envelope
mutations is compared to the co-receptor tropism of a genetically
defined virus that lacks the specific mutations under evaluation.
The ability of a specific mutation to confer altered co-receptor
tropism is confirmed or disproved by introducing the mutation into
well-characterized reference virus and evaluating the co-receptor
tropism of the mutant virus in the virus entry assay as described
in Example 4. Observed changes in co-receptor tropism are
attributed to the specific mutations introduced into the pHIVenv
vector.
[0229] In one embodiment of the invention, genetic determinants of
R5 tropism are identified by evaluating amino acid sequences within
the V3 loop of the gp120 surface envelope protein. The amino acid
sequences under evaluation are identified by comparing the amino
acid sequences of large numbers of X4 tropic and R5 tropic viruses.
Consistent differences between the X4 and R5 viruses are selected
for evaluation. Isogenic viruses based on an well-characterized X4
parental clone (e.g NL4-3, HXB2) containing specific "R5 candidate"
mutations in the V3 loop of the gp120envelope protein are
constructed by site directed mutagenesis and tested for co-receptor
tropism as described in Example 4. Cells expressing CD4 plus CCR5
(e.g. U-87/CD4/CCR5) or CD4 plus CXCR4 (U-97/CD4/CXCR4) are
infected in the absence of an R5 (piperidin-1yl butane compound)
and X4 (AMD3100) inhibitor and in the presence of inhibitory
concentrations of R5 and X4 drug concentrations. Amino acid
substitutions that change the X4 tropic virus to an R5 tropic virus
are characterized as genetic determinants of R5 tropism.
[0230] In a related embodiment of the invention, genetic
determinants of X4 tropism are identified by evaluating amino acid
sequences within the V3 loop of the gp120surface envelope protein.
The amino acid sequences under evaluation are identified by
comparing the amino acid sequences of large numbers of X4 tropic
and R5 tropic viruses. Consistent differences between the X4 and R5
viruses are selected for evaluation. Isogenic viruses based on an
well-characterized R5 parental clone (e.g JRCSF) containing
specific "X-4-candidate" mutations in the V3 loop of the gp120
envelope protein are constructed by site directed mutagenesis and
tested for co-receptor tropism as described in Example 4. Cells
expressing CD4 plus CCR5 (e.g. U-87/CD4/CCR5) or CD4 plus CXCR4
(U-87/CD4/CXCR4) are infected in the absence of an R5
(piperidin-1yl butane compound) and X4 (AMD3100) inhibitor and in
the presence of inhibitory concentrations of R5 and X4 drug
concentrations. Amino acid substitutions that change the X4 tropic
virus to an R5 tropic virus are characterized as genetic
determinants of R5 tropism.
[0231] In a related embodiments of the invention, genetic
determinants of X4 or R5 tropism are identified by evaluating amino
acid sequences within the entire gp120 surface envelope
protein.
[0232] In a related embodiment of the invention, genetic
determinants of X4 or R5 tropism are identified by evaluating amino
acid sequences within the gp41transmembrane envelope protein.
[0233] In a related embodiment of the invention, genetic
determinants that specify the use of co-receptors other than CCR5
and CXCR4 are identified by evaluating amino acid sequences within
the V3 loop of the gp120surface envelope protein. The amino acid
sequences under evaluation are identified by comparing the amino
acid sequences of viruses that are able to replicate on cells that
do not express CXCR4 or CCR5, but do express other candidate
co-receptors. Consistent differences in amino acid sequences
between these non-X4, non R5 viruses and the X4 and R5 viruses are
selected for evaluation. Isogenic viruses based on an
well-characterized X4 (e.g. NL4-3) or R5 (e.g. JRCSF) parental
clone containing specific "non-X4, non-R5 candidate" mutations in
the V3 loop of the gp120envelope protein are constructed by site
directed mutagenesis and tested for co-receptor tropism as
described in Example 4. Cells expressing CD4 plus CCR5 (e.g.
U-87/CD4/CCR5), CD4 plus CXCR4 (U-87/CD4/CXCR4), and CD4 plus other
candidate co-receptors (U-87/CD4/X) are infected in the absence of
an R5 (piperidin-1yl butane compound) and X4 (AMD3100) inhibitor
and in the presence of inhibitory concentrations of R5 and X4 drug
concentrations. Amino acid substitutions that confeys tropism for a
non-X4, non-R5 co-receptor are characterized as genetic
determinants of tropism for the specific co-receptor.
[0234] In a related embodiments of the invention, genetic
determinants of tropism for other co-receptors are identified by
evaluating amino acid sequences within the entire gp120 surface
envelope protein.
[0235] In a related embodiment of the invention, genetic
determinants of tropism for other co-receptors are identified by
evaluating amino acid sequences within the gp41 transmembrane
envelope protein.
[0236] In another embodiment of the invention, genetic determinants
that specify the use of CD8 (in addition to, or instead of CD4) as
a receptor for HIV-1 are identified by evaluating amino acid
sequences within the V3 loop of the gp120 surface envelope protein.
The amino acid sequences under evaluation are identified by
comparing the amino acid sequences of viruses that are able to
replicate in cells that do not express CD4, but do express CD8.
Consistent differences in amino acid sequences between these CD4
tropic viruses and CD8 tropic viruses are selected for evaluation.
Isogenic viruses based on an well-characterized CD4 tropic (e.g.
NL4-3, JRCSF) parental clones containing specific "CD8 candidate"
mutations in the V3 loop of the gp120 envelope protein are
constructed by site directed mutagenesis and tested for CD8
receptor tropism as described in Example 4. Cells expressing CD4
plus CCR5 (e.g. U-87/CD4/CCR5), CD4 plus CXCR4 (U-87/CD4/CXCR4),
CD8 plus CCR5 (e.g. U-87/CD8/CCR5), CD8 plus CXCR4 (U-87/CD8/CXCR4)
are infected. Amino acid substitutions that enable replication in
cells that express CD8 but not CD4 are characterized as genetic
determinants of CD8 tropism.
[0237] In a related embodiments of the invention, genetic
determinants of CD8 tropism are identified by evaluating amino acid
sequences within the entire gp120 surface envelope protein.
[0238] In a related embodiment of the invention, genetic
determinants of CD8 tropism are identified by evaluating amino acid
sequences within the gp41transmembrane envelope protein.
EXAMPLE 6
[0239] Measuring HIV-1 Antibody Neutralization
[0240] This example provides a means and method for evaluating
antibody mediated neutralization of HIV-1, also referred to as
virus neutralization in this application. This example also
provides a means and method for evaluating the virus neutralization
activity of antibodies within HIV-1 infected patients. This example
also provides a means and method for evaluating the virus
neutralizing activity of antibodies within individuals or animals
vaccinated with therapeutic vaccines and vaccine candidates. This
example also provides a means and method for evaluating the virus
neutralizing activity of antibodies within individuals or animals
vaccinated with protective (preventative or prophylactic) vaccine
and vaccine candidates. This example also provides a means and
method for evaluating the virus neutralizing activity or
preparations of specific monoclonal or polyclonal antibodies.
[0241] Envelope sequences derived from patient samples, or
individual clones derived from patient samples, or envelope
sequences engineered by site directed mutagenesis to contain
specific mutations, are tested in the entry assay to evaluate
antibody mediated neutralization.
[0242] In one embodiment, antibody mediated neutralization is
evaluated in longitudinal patient samples (viruses collected from
the same patient at different time points) is evaluated. For
example, virus neutralization is evaluated prior to vaccination,
during a course of vaccination, and at incremental time points
after the course of vaccination is completed. In a related
embodiment, the sera of animals including, but not limited to,
mice, rats, rabbits, pigs, and cattle, are evaluated prior to
inoculation with candidate vaccines, during a course of repeated
inoculation, and at incremental time points after the course of
inoculation is completed. In one embodiment, virus neutralization
is evaluated for preventative vaccines and vaccine candidates. In
another embodiment, virus neutralization is evaluated for
therapeutic vaccines.
[0243] In another embodiment, virus neutralization is evaluated for
samples collected from a large number of different patients. In a
further embodiment, virus neutralization is evaluated for samples
collected from a large number of patients representing different
patient populations and different virus populations. "Patient
populations" may include, but are not limited to, newly infected
patients, chronically infected patients, patients with advanced
HIV/AIDS disease, patients with rapid disease progression, patients
with slow disease progression (typically referred to as long term
non-progressors) patients undergoing antiretroviral therapy or
immuno-therapy (e.g. interleukin-2, or other cytokines), vaccinated
and unvaccinated individuals. "Virus populations" nay include, but
are not limited to, viruses with distinct genetic characteristics
and geographical or gins (clade A, B, C, D, E, F, G) , viruses
susceptible to antiretroviral drugs, viruses with reduced
susceptibility/resistance to antiretroviral drugs, primary
isolates, isolates adapted for growth in cell culture (often
referred to as lab-adapted viruses), syncytia inducing (SI)
viruses, non-syncytia inducing (NSI) viruses, macrophage (M) tropic
viruses, T-cell (T) tropic viruses and dual tropic (M and T)
viruses.
[0244] Characterization of Patient Antibody (Patient Antibody vs.
Standard Virus Panel)
[0245] In this embodiment, the assay is performed using a target
cell line that expresses the HIV-1 receptor CD4 plus the HIV-1
co-receptors CCR5 and CXCR4 (HT4/CCR5/CXCR4). Such a cell line is
capable of evaluating the neutralizing activity of antibodies for
bolh R5 and X4 tropic viruses. In a related embodiment, the assay
is performed using two target cell lines. One cell line expresses
CD4 plus CCR5 (U-87/CD4/CCR5) and is used to test R5 tropic
viruses. Another cell line expresses CD4 plus CXCR4
(U-87/CD4/CXCR4) and is used to evaluate X4 tropic viruses. The
virus entry assay is performed by infecting individual target cell
cultures with recombinant virus stocks derived from packaging host
cells transfected with pHIVenv and pHIVluc or pHIVlucDU3 vectors.
In this embodiment, pHIVenv vectors contain envelope sequences of
specific, well-characterized viruses and express the HIV-1 envelope
proteins (gp120SU, gp41TM). Sucn viruses represent a "standard
virus panel" (see above description of virus population). Some, but
not all, reasonable examples of viruses that may constitute a
standard panel are listed in Table 4. A standard virus panel is
used to compare the neutralizing antibody activity of sera obtained
from many different patients and/or animals (see above description
of patient population). In this embodiment viruses are evaluated
using target cells cultured in 96 well plates. Typically, target
cells are plated at 5,000 cells per well for HT4/CCR5/CXCR4 or
10,000 cells per well for U-87/CD4/CCR5 and U-87/CD4/CXCR4 one day
prior to infection. Prior to target cell infection, each virus
stock is pre-incubated with the sera or antibody preparation
(typically for 1 h) that is being evaluated. The sera or antibody
preparations are tested undiluted and at incrementally greater
dilutions (typically four to five serial 10-fold dilutions).
Infection of target cells with each virus stock is also performed
in the absence of antibody (no antibody). Virus neutralization is
assessed by comparing the amount of luciferase activity produced in
target cells, both in the presence and absence of antibody. In this
embodiment, the results of the assay are interpreted by comparing
the ability of each antibody to preferentially block infection of
target cells (reduce or eliminate luciferase activity). Virus
neutralization activity is quantified by noting the highest
antibody dilution (most dilute) that is able to block target cell
infection (e.g. the highest dilution that is able to reduce the
luciferase activity produced in the absence of antibody by
50%).
[0246] Characterization of Patient HIV-1 (Patient Virus vs.
Standard Antibody Panel)
[0247] In this embodiment, the assay is performed using a target
cell line that expresses the HIV-1 receptor CD4 plus the HIV-1
co-receptors CCR5 and CXCR4 (HT4/CCR5/CXCR4). Such a cell line is
capable of evaluating the neutralizing activity of antibodies for
both R5 and X4 tropic viruses. In a related embodiment, the assay
is performed using two target cell lines. One cell line expresses
CD4 plus CCR5 (U-87/CD4/CCR5) and is used to test R5 tropic
viruses. Another cell line expresses CD4 plus CXCR4
(U-87/CD4/CXCR4) and is used to evaluate X4 tropic viruses. The
virus entry assay is performed by infecting individual target cell
cultures with recombinant virus stocks derived from packaging host
cells transfected with pHIVenv and pHIVluc or pHIVlucDU3 vectors.
In this embodiment, pHIVenv vectors contain patient virus derived
envelope sequences and express HIV-1 envelope proteins (gp120SU,
gp41TM). In this embodiment, viruses from different patient
populations (see above description of patient population), and/or
different virus populations (see above description for virus
population) are used to construct pHIVenv vectors. Pseudotyped HIV
derived from pHIVenv vectors are evaluated in the virus entry assay
to determine if they are susceptible to neutralization by a panel
of specific, well-characterized antibody preparations. Such
antibodies represent a "standard antibody panel". Some, but not
all, reasonable examples of antibodies that may constitute a
standard panel are listed in Table 4. In this embodiment virus
neutralization is evaluated using target cells cultured in 96 well
plates. Typically, target cells are plated at 5,000 cells per well
for HT4/CCR5/CXCR4 or 10,000 cells per well for U-87/CD4/CCR5 and
U-87/CD4/CXCR4 one day prior to infection. Prior to infection, each
patient derived virus stock is incubated with the each of the
antibody preparations (typically for 1 h) in the standard antibody
panel. The sera or antibody preparations are tested undiluted and
at various dilutions (typically four to five serial 10-fold
dilutions). Infection of target cells with each virus stock is also
performed in the absence of drug (no drug). Virus neutralization is
assessed by comparing the amount of luciferase activity produced in
target cells, both in the presence and absence of antibody. In this
embodiment, the results of the assay are interpreted by comparing
the ability of each antibody to preferentially block infection of
target cells (reduce or eliminate luciferase activity). Virus
neutralization activity is quantified by noting the highest
antibody dilution (most dilute) that is able to block target cell
infection (e.g. the highest dilution that is able to reduce the
luciferase activity produced in the absence of antibody by
50%).
EXAMPLE 7
[0248] Identifying HIV-1 Envelope Amino Acid Sequences that Elicit
Alter, or Prevent Neutralizing Antibody Responses
[0249] This example provides a means and method for identifying
HIV-1 envelope amino acid sequences that elicit/promote, or alter,
or prevent antibody mediated neutralization of HIV-1 infection
(also referred to as virus neutralization in this application).
[0250] Envelope sequences derived from patient samples, or
individual clones derived from patient samples, or envelope
sequences engineered by site directed mutagenesis to contain
specific mutations, are tested in the entry assay to determine
co-receptor tropism as described in Example 6.
[0251] In one embodiment, antibody mediated neutralization is
evaluated in longitudinal patient samples (viruses collected from
the same patient at different time points) is evaluated. For
example, virus neutralization is evaluated prior to vaccination,
during a course of vaccination, and at incremental time points
after the course of vaccination is completed. In one embodiment,
virus neutralization is evaluated for preventative vaccines. In
another embodiment, virus neutralization is evaluated for
therapeutic vaccines.
[0252] In another embodiment, virus neutralization is evaluated for
samples collected from a large number of different patients. In a
further embodiment, virus neutralization is evaluated for samples
collected from a large number of patients representing different
virus and patient populations. Such patient populations may
include, but are not limited to, newly infected patients,
chronically infected patients, patients with advanced disease,
patients undergoing antiretroviral therapy or immuno-therapy,
vaccinated and unvaccinated individuals. Such virus populations may
include, but are not limited to, viruses with distinct genetic
characteristics (clade A, B, C, D, E, F, G), viruses susceptible to
antiretroviral drugs, viruses with reduced
susceptibility/resistance to antiretroviral drugs, primary isolates
or isolates adapted for growth in cell culture (often referred to
as lab-adapted viruses), syncytia inducing (SI) viruses or
non-syncytia inducing (NSI) viruses, macrophage (M) tropic viruses,
T-cell (T) tropic viruses and dual tropic (M and T) viruses.
[0253] Genotypic Analysis of Patient HIV Samples
[0254] Envelope sequences representing patient sample pools, or
clones derived from patient pools, can be analyzed by any broadly
available DNA sequencing methods. In one embodiment of the
invention, patient HIV sample sequences are determined using viral
RNA purification, RT/PCR and dideoxynucleotide chain terminator
sequencing chemistry and capillary gel electrophoresis (Applied
Biosystems, Foster City, Calif.). Envelope sequences of patient
virus pools or clones are compared to reference sequences, other
patient samples, or to a sample obtained from the same patient
prior to initiation of therapy, if available. The genotype is
examined for sequences that are different from the reference or
pre-treatment sequence and correlated to differences in entry
inhibitor susceptibility.
[0255] Antibody Mediated Neutralization of Genetically
Characterized Viruses
[0256] Envelope amino acid sequences that correlate with virus
neutralization are evaluated by constructing envelope expression
vectors (pHIVenv) containing a specific mutation on a defined
genetic background (e.g. NL4-3 for X4 tropism, JRCSF for R5
tropism). Mutations may be incorporated alone and/or in combination
with other mutations that are thought to modulate virus
neutralization. Envelope mutations are introduced into pHIVenv
vectors using any of the broadly available methods for
site-directed mutagenesis. In one embodiment of this invention the
mega-primer PCR method for site-directed mutagenesis is used
(Sarkar, G. and Summer, S. S., 1990). A pHIVenv vector containing a
specific envelope mutation or group of mutations are tested using
the virus entry assay described in Example 6. Specific antibody
preparations (i.e. well-characterized monoclonal of polyclonal
antibody preparations), serum from HIV infected patients, or serum
from vaccinated individuals can be selected to compare neutralizing
activity. Antibody neutralization of the virus containing envelope
mutations is compared to antibody neutralization of a genetically
defined virus that lacks the specific mutations under evaluation.
The ability of a specific mutation to confer, alter, or prevent
antibody neutralization is confirmed or disproved by introducing
the mutation into well-characterized reference virus and evaluating
the antibody mediated neutralization of the mutant virus in the
virus entry assay as described in Example 6. Observed changes in
virus neutralization are attributed to the specific mutations
introduced into the pHIVenv vector.
[0257] In one embodiment of the invention, genetic determinants of
virus neutralization are identified by evaluating amino acid
sequences within the V3 loop of the gp120surface envelope protein.
The amino acid sequences under evaluation are identified by
comparing the amino acid sequences of large numbers of viruses that
can, or cannot be neutralized by various well-characterized
antibody preparations, patient sera, or sera from vaccinated
individuals. Consistent differences in V3 loop amino acid sequences
between viruses that can, or cannot be neutralized are selected for
evaluation. Isogenic viruses based on an well-characterized
parental clone (e.g NL4-3, HXB2, JRCSF) containing specific "virus
neutralization candidate" mutations in the V3 loop of the
gp120envelope protein are constructed by site directed mutagenesis
and tested for antibody mediated neutralization as described in
Example 6. Cells expressing CD4 plus CCR5 (e.g. U-87/CD4/CCR5), CD4
plus CXCR4 (U-87/CD4/CXCR4), or CD4 plus CCR5 -and CXCR4
(HT4/CCR5/CXCR4) are infected. Amino acid substitutions that change
that elicit, alter, or prevent antibody neutralization are deemed
important to virus neutralization.
[0258] In a related embodiment of the invention, genetic
determinants of virus neutralization are identified by evaluating
amino acid sequences within the entire gp120 surface envelope
protein.
[0259] In a related embodiment of the invention, genetic
determinants of virus neutralization are identified by evaluating
amino acid sequences within the gp41 transmembrane envelope
protein.
EXAMPLE 8
[0260] Measuring Susceptibility to Virus Entry Inhibitors to Guide
Treatment Decisions
[0261] This example provides a means and method for using virus
entry inhibitor susceptibility to guide the treatment of HIV-1.
This example further provides a means and method for using virus
entry inhibitor susceptibility to guide the treatment of patients
that have received previous antiretroviral treatment with a virus
entry inhibitor. This invention further provides the means and
methods for using virus entry inhibitor susceptibility to guide the
treatment of patients that have not received previous treatment
with a virus entry inhibitor.
[0262] In one embodiment, the susceptibility of patient's viruses
to Ad rus entry inhibitors is used to guide the treatment of
patients failing antiretroviral regimens that include one or more
virus entry inhibitors. Treatment failure (also referred to as
virologic failure) is generally defined as partially suppressive
antiviral treatment resulting in detectable levels of virus, which
is typically measured in the patient plasma). Guidance may include,
but is not limited to, (a) clarification of available drug
treatment options, (b) selection of more active treatment regimens,
(c) clarification of the etiology of rising viral load in treated
patients (i.e. poor adherence, drug resistance), and (d) reduction
in the use of inactive and potentially toxic drugs. In this
embodiment, resistance test vectors are derived from a patient
virus samples and tested for susceptibility to various virus entry
inhibitors using the pherotypic virus entry assay. Virus entry
inhibitors may include, but are not limited to, fusion inhibitors
(e.g. T-20, T-1249), co-receptors antagonists (AMD3100, AMD8664,
TAK779, PRO542, and piperidin-1yl butane compounds) and CD4
antagonists (MAb 5A8). Appropriate treatment decisions are based on
the results of the virus entry assay (e.g. see FIG. 4B) and
additional relevant laboratory test results and clinical
information.
[0263] In another embodiment, the susceptibility of patient's
viruses to virus entry inhibitors is used to guide the treatment of
patients that have not been previously treated with antiretroviral
regimens that include one or more virus entry inhibitors. Guidance
may include, but is not limited to, (a) clarification of available
drug treatment options, (b) selection of more active treatment
regimens, (c) clarification of the baseline susceptibility to virus
entry inhibitors, and (d) reduction in the use of inactive and
potentially toxic drugs. Determining baseline susceptibility of
virus entry inhibitors in treatment naive patients is important for
two reasons. First, the natural susceptibility of viruses to entry
inhibitors can vary widely (e.g. see FIG. 4A). Second, the
increased use of virus entry inhibitors will undoubtedly result in
the generation drug resistant variants that can be transmitted to
newly infected individuals. In this embodiment, resistance test
vectors are derived from a patient virus samples and tested for
susceptibility to various virus entry inhibitors using the
phenotypic virus entry assay. Virus entry inhibitors may include,
but are not limited to, fusion inhibitors (e.g. T-20, T-1249),
co-receptors antagonists (AMD3100, AMD8664, TAK779, PRO542, and
piperidin-1yl butane compounds) and CD4 antagonists (MAb 5A8).
Appropriate treatment decisions are based on the results of the
virus entry assay and additional relevant laboratory test results
and clinical information.
EXAMPLE 9
[0264] Measuring HIV-1 Co-receptor Tropism to Guide Treatment
Decisions
[0265] This example provides a means and method for using HIV-1
co-receptor (CCR5, CXCR4) tropism to guide the treatment of HIV-1.
This example further provides a means and method for using HIV-1
co-receptor tropism to guide the treatment of patients failing
antiretroviral drug treatment. This invention further provides the
means and methods for using HIV-1 co-receptor tropism to guide the
treatment of patients newly infected with HIV-1.
[0266] This example provides a means and method for using virus
HIV-1 co-receptor tropism to guide the treatment of HIV-1. This
example further provides a means and method fur using HIV-1
co-receptor tropism to guide the treatment of patients that have
received previous antiretroviral treatment with a virus entry
inhibitor. This invention further provides the means and methods
for using HIV-1 co-receptor tropism to guide the treatment of
patients that have not received previous treatment with a virus
entry inhibitor.
[0267] In one embodiment, the co-receptor tropism of a patient's
virus is used to guide the treatment of a patient failing
antiretroviral regimens that include one or more co-receptor
antagonists. Treatment failure (also referred to as virologic
failure) is generally defined as partially suppressive antiviral
treatment resulting in detectable levels of virus, which is
typically measured in the patient plasma). Guidance may include,
but is not limited to, (a) clarification of the etiology of rising
viral load in treated patients (i.e. poor adherence, drug
resistance, change in co-receptor tropism), (b) clarification of
available drug treatment options, (c) selection of more active
treatment regimens, and (d) reduction in the use of inactive and
potentially toxic drugs. Monitoring co-receptor tropism in patients
receiving treatment with CCR5 antagonists has clinical
significance, since drug pressure may result in a switch to CXCR4
co-receptor tropism. X4 viruses (CXCR4 co-receptor tropism) are
associated with a poorer prognosis compared to R5 viruses (CCR5
co-receptor tropism). In this embodiment, resistance test vectors
are derived from a patient virus samples and tested for
susceptibility to various co-receptor antagonists using the
phenotypic virus entry assay. Co-receptor antagonists may include,
but are not limited to, AMD3100, AMD8664, TAK779, PRO542, and
piperidin-1yl butane compounds. Appropriate treatment decisions are
based on the results of the virus entry assay (e.g. see FIG. 4B)
and additional relevant laboratory test results and clinical
information.
[0268] In another embodiment, co-receptor tropism of a patient's
virus is ised to guide the treatment of patients that have not been
previously treated with antiretroviral regimens that include one or
more co-receptor antagonists. Guidance may include, but is not
limited to, (a) clarification of the baseline co-receptor tropism,
(b) clarification of available drug treatment options, (c)
selection of more active treatment regimens, (d) reduction in the
use of inactive and potentially toxic drugs. Determining baseline
co-receptor tropism has significant clinical significance.
Treatment with the appropriate co-receptor antagonist (R5 vs. X4
tropism), or antagonists (dual tropism or mixed tropism) is likely
to result in a more potent and durable response. In this
embodiment, resistance test vectors are derived from a patient
virus samples and tested for susceptibility to various virus entry
inhibitors using the phenotypic virus entry assay. Co-receptors
antagonists may include, but are not limited to, AMD3100, AMD8664,
TAK779, PRO542, and piperidin-1yl butane compounds. Appropriate
treatment decisions are based on the results of the virus entry
assay and additional relevant laboratory test results and clinical
information.
[0269] References
[0270] 1. Adachli, A., H. E. Gendelman, S. Koenig, T. Folks, R.
Caney, A. Rabson, and M. A. Martin. 1986. Production of Acquired
Immunodeficiency Syndrome-associated Retrovirus in Human and
Nonhuman Cells Transfected with an Infectious Molecular Clone. J.
Virol. 59:284-291.
[0271] 2. Alkhatib, G., C. Combadiere, C. C. Broder, Y. Feng, P. E.
Kennedy, P. M. Murphy, and E. A. Berger. 1996. CC CKR5: A Rantes,
MIP-1alpha, MIP-1 Beta Receptor as a Fusion Cofactor for
Macrophage-tropic Hiv-1. Science 272:1955-8.
[0272] 3. Allaway G. P., Ryder A. M., Beaudry G. A., and Maddon P.
J. 1993. Synergistic Inhibition of HIV-1 Envelope-Mediated Cell
Fusion by CD4-based Molecules in Combination with Antibodies to
Gp120 or Gp41. Aids Res. Hum. Retroviruses 9:581-7.
[0273] 4. Baba, M., O. Nishimura, N. Kanzaki, M. Okamoto, H.
Sawada, Y. Iizawa, M. Shiraishi, Y. Aramaki, K. Okonogi, Y. Ogawa,
K. Meguro, and M. Fujino. 1999. A Small-molecule, Nonpeptide CCR5
Antagonist with Highly Potent and Selective Anti-hiv-1 Activity.
Proc. Natl. Acad. Sci. USA 96:5698-703.
[0274] 5. Baxter, J., D. Mayers, D. Wentworth, J. Neaton, and T.
Merigan. 1999. A Pilot Study of the Short-term Effects of
Antiretroviral Management Based on Plasma Genotypic Antiretroviral
Resistance Testing (Gart) in Patients Failing Antiretroviral
Therapy. Presented at the 6th Conference on Retroviruses and
Opportunistic Infections. Chicago, Ill.
[0275] 6. Bernard P., Kezdy K. e., Van Melderen L., Steyaert J.,
Wyns L., Pato M. l., Higgins P. N., and Couturier M. 1993. The F
Plasmid CcdB protein Induces Efficient ATP-dependent Dna Cleavage
by Gyrase. J. Mol. Biol. 23:534-41.
[0276] 7. Bernard, P. and Couturier, M. 1992. Cell Killing by the F
Plasmid Ccdb protein Involves Poisoning of DNA-topoisomerase II
Complexes. J. Mol. Bio. 226:735-45.
[0277] 8. Bleul, C. C., M. Farzan, H. Choe, C. Parolin, I.
Clark-Lewis, J. Sodroski, and T. A. Springer. 1996. The Lymphocyte
Chemoattractant Sdf-1 Is a Ligand for Lestr/fusin and Blocks Hiv-1
Entry. Nature 382:829-33.
[0278] 9. Bridger G. J, Skerlj R. T., Padmanabhan S., Martellucci
S. A., Henson G. W., Struyf S., Witvrouw M., Schols D., and De
Clercq E. 1999. Synthesis and Structure-activity Relationships of
Phenylenebis(methylene)- -linked Bis-azamacrocycles That Inhibit
HIV-1 and HIV-2 Replication by Antagonism of the Chemokine Receptor
CXCR4. J. Med. Chem. 42:3971-81.
[0279] 10. Carpenter, C. J., Cooper D. A., Fischl, M. A., Gatell J.
M., Gazzard B. G., Hammer S. M., Hirsch M. s., Jacobsen D. M.,
Katzenstein D. A., Montaner J. S., Richman D., Saag M. S.,
Schechter M., Schooley R. T., Thompson M. A., Vello S., Yeni P. G.,
and Volberding P. A. 2000. Antiretroviral Therapy in Adults. JAMA
283:381-89.
[0280] 11. CDC (Centers for Disease Control and Prevention).
HIV/AIDS Surveillance Report, 1999;11(no. 1).
[0281] 12. Coffin, J. m. 1995. HIV Population Dynamics in Vivo:
Implications for Genetic Variation Pathogenesis, and Therapy.
Science 267:483-489.
[0282] 13. DHHS (Department of Health and Human Services). Henry
Kaiser Family Foundation: Guidelines for the Use of Antiretrovirals
Agents in, HIV-infected Adults and Adolescents. (Jan. 28,
2000).
[0283] 14. Gerdes, K., L. k. Poulsen. T. Thisted, A. k. Nielson; J.
MaRTInussen, and P. h. Andreasen. 1990. The Hok Killer Gene Family
in Gram-negative Bacteria. The New Biologist: 2:946-956.
[0284] 15. Hertogs, K., M.-p. De Bthune, V. Miller, T. Ivens, P.
Schel, A. V. Cauwenberge, C. Van Den Eynde, V. Van Gerwen, H.
Azijn, M. Van Houtte, F. Peeters, S. Staszewski, M. Conant, S.
Bloor, S. Kemp, B. Larder, and R. Pauwels. 1998. A Rapid Method for
Simultaneous Detection of Phenotypic Resistance to Inhibitors of
protease and Reverse Transcriptase in Recombinant Human
Immunodeficiency Virus Type 1 Isolates from Patients Treated with
Antiretroviral Drugs. Antimicrob. Agents Chemother. 42:269-276.
[0285] 16. Hwang, J.-j., L. Li, W. f. Anderson. 1997. A Conditional
Self-inactivating Retrovirus Vector That Uses a
Tetracycline-responsive Expression System. J. Virol. 71:
7128-7131.
[0286] 17. Japour, A. J., D. L. Mayers, V. A. Johnson, D. R.
Kuritzkes, L. A. Beckett, J.-m. Arduino, J. Lane, B. R. j., P. S.
Reichelderfer, R. T. D-aquila, C. S. Crumpacker, T. R.-s. Group, T.
A. C. T. Group, and V. C. R. W. Group. 1993. Standardized
Peripheral Blood Mononuclear Cell Culture Assay for Determination
of Drug Susceptibilities of Clinical Human Immunodeficiency Virus
Type 1 Isolates. Antimicrob. Agents Chemother. 37:1095-1101.
[0287] 18. Judice J. k., Tom J. y., Huang W., Wrin T., Vennari J.,
Petropoulos C. j., and Mcdowell R. s. 1997. Inhibition of HIV Type
1 Infectivity by Constrained Alpha-helical Peptides: Implications
for the Viral Fusion Mechanism. proc. Natl. Acad. Sci. U S a
94:13426-30.
[0288] 19. Kilby J m, Hopkins S, Venetta T m, Dimassimo B, Cloud G
a, Lee J y, Alldredge L, Hunter E, Lambert D, Bolognesi D, Matthews
T, Johnson M r, Nowak M a, Shaw G m, and Saag M s. 1998. Potent
Suppression of Hiv-1 Replication in Humans by T-20, a Peptide
Inhibitor of Gp41-mediated Virus Entry. Nat Med 4:1302-7.
[0289] 20. Mascola, J. r., G. Stiegler, T. c. Vancott, H. Katinger,
C. b. Carpenter, C. e. Hanson, H. Beary, D. Hayes, S. s. Frankel,
D. l. Birx, and M. g. Lewis. 2000. protection of Macaques Against
Vaginal Transmission of a Pathogenic Hiv-1/siv Chimeric Virus by
Passive Infusion of Neutralizing Antibodies. Nature Med.
6:207-210.
[0290] 21. Miyoshi, H., B. Ulrike, M. Takahashi, F. h. Gage, and I.
m. Verma. 1998. Development of a Self-inactivating Lentivirus
Vector. J. Virol. 72:8150-5157.
[0291] 22. Naviaux, R. k., E. Costanzi, M. Haas, and I. m. Verma.
1996. The Pcl Vector System: Rapid production of Helper-free,
High-titer, Recombinant Retroviruses. J. Virol. 70: 5701-5705.
[0292] 23. Petropoulos, C. j., N. t. Parkin, K. l. Limoli, Y. s.
Lie, T. Wrin, W. Huang, H. Tian, D. Smith, G. a. Winslow, D. Capon
and J. m. Whitcomb. 2000. A Novel Phenotypic Drug Susceptibility
Assay for Hiv-1. Antimicrob. Agents & Chem. 44:920-928.
[0293] 24. Phrma (Pharmaceutical Research and Manufacturers of
America). New Medicines in Development for Aids 1999.
Http://www.phrma.ora.
[0294] 25. Piketby, C., E. Race, P. Castiel, L. Belec, G. Peytavin,
A. Si-mohamed, G. Gonzalez-canali, L. Weiss, F. Clavel, and M.
Kazatchkine. 1999. Efficacy of a Five-drug Combination Including
Ritonavir, Saquinavir and Efavirenz in Patients Who Failed on a
Conventional Triple-drug Regimen: Phenotypic Resistance to protease
Inhibitors predicts Outcome of Therapy. Aids: 13:f71-f77.
[0295] 26. Porter, C. c., K. v. Lukacs, G. Box, Y. Takeuchi, and M.
k. l. Collins. 1998. Cationic Liposomes Enhance the Rate of
Transduction by a Recombinant Retroviral Vector in Vitro and in
Vivo. J. Virol. 72:4832-4840.
[0296] 27. Reimann K. a., Cate R. l., Wu Y., Palmer L., Olson D.,
Waite B. c., Letvin N. l., and Burkly L. c. 1995. In Vivo
Administration of CD4-specific Monoclonal Antibody: Effect On
provirus Load in Rhesus Monkeys Chronically Infected with the
Simian Immunodeficiency Virus of Macaques. Aids Res Hum.
Retroviruses 11:517-25
[0297] 28. Retroviruses. Coffin, J., S. Hughes, H. Varmus (Eds).
1997. Cold Spring Harbor Laboratory press, Cold Spring Harbor,
N.Y.
[0298] 29. Richman, D. 1998. Nailing down Another HIV Target.
Nature Med. 4:1232-1233.
[0299] 30. Rimsky, L. T., D. C. Shugars, and T. J. Matthews. 1998.
Determinants of Human Immunodeficiency Virus Type 1 Resistance to
Gp41-derived Inhibitory Pepitides. J. Virol. 72:986-993.
[0300] 31. Rodriguez-rosado, R., Briones, C. and Soriano, V. 1999.
Introduction of HIV Drug-resistance Testing in Clinical practice.
Aids 13:1007-1014.
[0301] 32. Schinazi, R. f, Larder, B. a., and Mellors, J. w. 1999.
Mutations in Retroviral Genes Associated with Drug Resistance.
Intl. Antiviral News: 7:46-69
[0302] 33. Shi C., and J. w. Mellors. 1997. A Recombinant
Retroviral System for Rapid in Viva Analysis of Human
Immunodeficiency Virus Type 1 Susceptibility to Reverse
Transcriptase Inhibitors. Antimicrob. Agents Chemother
41:2781-2785.
[0303] 34. Stephenson, J. 1999. New Class of Anti-hiv Drugs. Jama
282:1994.
[0304] 35. Who, Unaids/world Health Organization. Report: Aids
Epidemic Update: December 1999.
Http://www.unaids.orp/publications/documents/epide- m iology.
[0305] 36. Wild, C., T. Oak, C. Mcdanal, D. Bolognesi, and T.
[0306] Matthews. 1992. A Synthetic Peptide Inhibitor of HIV
Replication: Correlation Between Solution Structure and Viral
Inhibition. Proc. Natl. Acad. Sci. USA 89:10537-10541.
[0307] 37. Zennou, V., F. Mammamo, S. Paulous, D. Mathez, and F.
Clavel. 1998. Loss of Viral Fitness Associated with Multiple Gag
and Gag-pol processing Defects in Human Immunodeficiency Virus Type
1 Variants Selected for Resistance to protease Inhibitors in Vivo.
J. Virol: 72:3300-06.
[0308] 38. Ziermann, R., K. Limoli, K. Das, E. Arnold, C. j.
Petropoulos, and N. t. Parkin. 2000. A Mutation in Hiv-1 protease,
N88s, That Causes in Vitro Hypersensitivity to Amprenavir. J.
Virol. 74:4414-4419.
[0309]
1TABLE 1 Cells Cell Receptor 5.25 CXCR4, CD4, CCR5 (not expressed
well) BONZO 5.25.Luc4.M7 CD4, CCR5, BONZO HOS.CD4.CCR5 CD4, CCR5
HOS.CD4.CXCR4 CD4, CXCR4 HOS.CD4 CD4, low level expression of CCR5
and CXCR4 HOS HT4 R5 GFP wt CD4, CXCR4, CCR5 HOS.CD4.CCR5.GFP.M7
#6* CD4, CXCR4, CCR5 P4.CCR5 CD4, CXCR4, CCR5 U87.CD4 CD4 U87.CD4
R5 CD4, CCR5 U87CD4 X4 CD4, CXCR4 MT2 CD4, CXCR4 MT4 CD4, CXCR4 PMI
CD4, CXCR4, CCR5 CEM NKr CCR5 CD4, CXCR4, CCR5
[0310]
2TABLE 2 Representative viruses and reagents Viruses Envelope.sup.a
Source 89.6, SF2 R5-X4/SI/B ARRRP.sup.b 92BR014, 92US076 R5-X4/SI/B
ARRRP JR-CSF, 91US005 RS/NSI/B ARRRP 91US054 SI/B ARRRP NL43, MN,
ELI X4/B ARRRP 92HT599 X4 ARRRP 92UG031 R5/NSI/A ARRRP (IN-HOUSE)
92TH014, 92TH026 R5/NSI/B ARRRP (IN-HOUSE) 92BR025, 93MW959 R5/SI/C
ARRRP (IN-HOUSE) 92UG035 R5/NSI/D ARRRP (IN-HOUSE) 92TH022, 92TH023
R5/NSI/E ARRRP (IN-HOUSE) 93BR020 R5-X4/SI/F ARRRP (IN-HOUSE)
Antibodies Epitope SOURCE Mabs 2F5, 1577 gp41 TM ARRRP Mabs IG1b12,
2G12, 17b, 48D gp120 SU ARRRP Neutralization sera #2, HIV-
Polyclonal ARRRP IG Entry inhibitors Target Source CD4-IG gp120 SU
Genentech CD4-IGG2 gp120 SU Adarc SCD4 Sigma Progenics T20 (DP178)
gp41 TM Trimeris Rantes, MIP1a/b CCR5 SIGMA/ARRRP SDF1a/b CXCR4
SIGMA/ARRRP AMD 3100 CXCR4 AnorMed Dextran sulfate, Heparin
Non-specific Sigma .sup.aR5 (CCR5 co-receptor), X4 (CXCR4
co-receptor) SI (syncytium inducing), NSI (non-syncytium inducing),
A, B, C, D, E, F (envelope dade designation) .sup.bAIDS Research
and Reference Reagent Program
[0311]
3TABLE 3 Primers Tested for the Amplification of HIV Envelope RT
PRIMERS RT env_N3 5'-GGA GCA TTT ACA AGC AGC MC ACA GC-3' RT env
9720 5'-TTC GAG TCA VAC CTC AGG TAC-3' RT env 9740 5'-AGA CCA ATG
ACT TAY AAG G-3' 5' PCR PRIMERS 5'env 5'-GGG CTC GAG ACC GGT CAG
TGG CM TGA GAG TGA AG-3' 5'env_Xho/Pin 5'-GGG CTC GAG ACC GGT GAG
GAG AAG ACA GTG GCA ATG A-3' 5'env_START 5'-GGG CTC GAG ACC GGT GAG
CAG AAG ACA GTG GCA ATG-3' 3' PCR PRIMERS 3'env 5'-GGG TCT AGA ACG
CGT TGC CAC CCA TCT TAT AGC AA-3' 3'env_Xba/Mlu 5'-GGG TCT AGA ACG
CGT CCA CU GCO ACC CAT BTT ATA GC-3' 3'env_STOP 5'-GGG TCT AGA ACG
CGT CCA CTT GCC ACC CAT BTT A-3' 3'delta CT 5'-GAT GGT CTA AGA CGC
TGT TCA ATA TCC CTG CCT AAC TC-3' All Experiments are located in
Virologic Book number 0188
[0312]
4TABLE 4 (Panel 1) Anti-HIV Drugs Generic Drug/Compound Name
Trademark Manufacturer RT inhibitors (NRTI, nucleotide analogs)
AZT, ZDV Zidovudine Retrovir Glaxo/Wellcome 3TC Lamivudine pivir
Glaxo/Wellcome AZT + 3TC Combivir Glaxo/Wellcome d4T Stavudine Zent
Bristol-Myers/Squibb ddl Didanosine Videx Bristol-Myers/Squibb ddC
Zalcitabine Hivid Hoffman La Roche 1592U89 Abacavir Ziagen
Glaxo/Wellcome AZT + 3TC + 1592U89 Trizivir Glaxo/Wellcome (-)FTC
(5-fluoro-3TC: Corviracil) Emtricitabine Triangle Pharmaceuticals
(-)FTC + (+)FTC (50:50) Racimir QuadPhamra DAPD DXG active
Amooxovir Triangle Pharmaceuticals F-ddA (2-fluoro-ddA) Lodenosine
Medimmune Oncology (US Bioscience) BCH-10652, dOTC BioChem Pharma,
Inc (2-deoxy-3-oxa-4-thiocytidine) D-d4FC Triangle Pharmaceuticals
(Schnazi) RT Inhibitors (NTRTI; nucleotide analogs bis-POC PMPA
(GS-4331) Tenofovir Gilead Sciences bis-POM PMEA (GS-840) Adefovir
dipivoxil Gilead Sciences RT Inhibitors (NNRTI, non-nucleoside
BI-RG-587 Nevirapine Viramurie Boehringer/Inglehelm (Roxanne) BHAP
PNU-90152T Delavirdine Rescriptor Pharmacia & Upjohn DMP 266
(L-743,726) Efavirenz Sustiva Dupont Pharmaceuticals (Avid) MKC442
(Coactinon) Emivirine Triangle/Mitsubishi Kassi AG-1549 (S1153) (on
hold) Capravirine Agouron Pharmaceuticals PNU-142721 Pharmacia
& Upjohn DPC-961, -963, -083, -08? DuPont Pharmaceuticals
SJ-3366 Also entry inhibitor? Samjin Phamaceuticals BHAP PNU-87201
Atevirdine Upjohn GW420867X (quinoxaline) (2.sup.nd gen. HBY 097)
Glaxo/Wellcome (Hoechst Bay r) TMC 120 (R147681) Tibotec TMC 125
(R165335) Tibotec R86183 tivirapine Janssen Pharmaceuticals
Calanolide A Sarawak Medichem Pharmacauticals Protease Inhibitors
(PRI) Ro 31-8959 Saquinavir-(hgc) Invirase Hoffman-La Roche
Saquinavir-(sgc) Fortivase MK-639 (L-735, 524) Indinavir Crixivan
Merck Research Laboratories ABT-538 (A-84538) Ritonavir Norvir
Abbott Laboratories AG1343 Nelfinavir Viracept Agouron
Pharmaceuticals 141W94 (VX-478) Amprenavir Agenerase
Glaxo-Wellcome/Vertx ABT-378/r Lopinavir/ritonavir Kaletra Abbott
Laboratories BMS 232,632 (aza-peptide) Bristol-Myers-Squibb
PNU-140690 Tipranavir Pharmacia & Upjohn DMP 450 (cyclic urea)
Mozenavir Triangle/Avid (ph I/II) TMC 126 (Erickson's compound)
Tibotec G/W433908 (VX-175) amprenavir pro-drug
Glaxo/Wellcome/Vertex L756, 423 (on hold) Merck PD-178390
(dihydropyrone) Parke Davis (Boehringer-Ingleheim) ? new candidate
Roche DPC 681 and 684 DuPont Pharmaceuticals AG-1776 (JE-2147 =
KNI-764) Agouron Pharmaceuticals Envelope/Receptor Inhibitors T-20
(gp41) Pentafuside Trimeris Pharmaceuticals T-1249 (gp41) Trimeris
Pharmaceuticals D-peptide inhibitor (gp41) small mol. SCM-C
Schering-Plough AMD-3100 (CXCR4) (bicyclam) AnorMED AMD-3664
(CXCR4) (macrocyclam) AnorMED ALX40-4C (CXCR4) U. PA FP21399 Fuji
Pharmaceuticals PRO 542 (gp120) CD4lgG2 Progenics Pharmaceuticals
PRO-140 (CCR5) MAb CCR5 Progenics Pharmaceuticals T-22 (CXCR4)
(peplide, 18-mer) Met-SDF-1 (CXCR4) TAK 779 (CCR5 antagonist)
Takeda AOP-Rantes (CCR5) Gryphon Sciences
[0313]
5TABLE 4 (Panel) Rantes 9-68(CCR5) CCR5 antagonists
4-(pipendin-1-yl) Merck 4 butane class .alpha.-Immunokine-NNS03
(CCR5, CXCR4) .alpha.-cobratoxin PhyloMed Corp. Integrase
Inhibitors AR-177 Zintevir Aronex Pharmaceuticals Diketo acids
Merck Research Laboratories Nucleocapsid Inhibitor RB 2121 cyclic
peptide p7 mimic (see PNAS 96:4886-4891 (1999)) CI-1012 Achelion
Pharmaceuticals RNase H Inhibitor SP1093V (BBNH Fe+ 3 derivative
(Pamiak) FDA approved drugs are shown in boldface red =
discontinued development, blue = not sure about development
status
[0314]
6TABLE 4 (Panel 3) Generic Name FDA Approval (abbreviation) Brand
Name Firm Date zidovudine, AZT Retrovir Glaxo Wellcome March 1987
didanosine, ddl Videx Bristol Myers-Squibb October 1991
zalcitabine, ddC Hivid Hoffman-La Roche June 1992 stavudine, d4T
Zerit Bristol Myers-Squibb June 1994 lamivudine, 3TC Epivir Glaxo
Wellcome November 1995 saquinavir, SQV, hgc Invirase Hoffman-La
Roche December 1995 saquinavir, SQV, sgc Fortovase Hoffman-La Roche
November 1997 ritonavir, RTV Norvir Abbott Laboratories March 1996
indinavir, IDV Crixivan Merck & Co., Inc. March 1996
nevirapine, NVP Viramune Boenringer Ingelheim June 1996 neifinavir,
NFV Viracept Agoiron Pharmaceuticals March 1997 delavirdine, DLV
Rescriptor Pharmacia & Upjohn April 1997 ZDV + 3TC Combivir
Glaxo Wellcome September 1997 efavirenz, EFV Sustiva DuPont
Pharmaceuticals September 1998 abacavir, ABC Ziagen Glaxo Wellcome
February 1999 amprenavir Agenerase Glaxo Wellcome April 1999
lopinavir/ritonavir Kaletra Abbott September 2000 ZDV + 3TC + ABC
Trizivir GlaxoSmithKline November 2000
[0315]
7 CORECEPTOR ASSAY SCREEN TEMPLATE drug: active RLU Intiut 100
tropisin ratio limit : CxCke : drug: AMC 1 2 3 4 5 6 R5 X4 R5:X4 R5
X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 no Drug
RLU L83 RLU AMD RLU z 13 14 15 16 17 18 R5 X4 R5:X4 R5 X4 R5:X4 R5
X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 no Drug RLU L83 RLU
AMD RLU z 25 26 27 28 29 30 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5
X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 no Drug RLU 997.12 L83 RLU AMD RLU
z 37 38 39 40 41 42 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4
R5 X4 R5:X4 R5 X4 R5:X4 no Drug RLU L83 RLU AMD RLU z 49 50 51 52
53 54 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4
R5 X4 R5:X4 no Drug RLU 0.02 1033.01 3370.10 L83 RLU AMD RLU z 61
62 63 64 65 66 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5
X4 R5:X4 R5 X4 R5:X4 no Drug RLU 94.23 16.36 16.19 120.67 L83 RLU
AMD RLU z 73 74 75 76 77 78 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5
X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 no Drug RLU 15.04 156.84 L83 RLU
AMD RLU z 85 86 87 88 89 90 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5
X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 no Drug RLU 15.45 16.59 14.88 0.08
0.00 L83 RLU AMD RLU z 7 8 9 10 11 12 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4
R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 no Drug RLU 0.02 0.04
602.94 0.04 458.63 0.00 L83 RLU AMD RLU z R5 X4 R5:X4 R5 X4 R5:X4
R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 no Drug RLU L83 RLU
AMD RLU z 19 20 21 22 23 24 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5
X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 no Drug RLU 0.02 217.29 63.65 0.66
322.30 L83 RLU AMD RLU z 31 32 33 34 35 36 R5 X4 R5:X4 R5 X4 R5:X4
R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 no Drug RLU 0.05
5.53 749.67 13.66 13.42 L83 RLU AMD RLU z 43 44 45 46 47 48 R5 X4
R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4
no Drug RLU 0.13 15.87 612.72 67.63 269.17 716.97 L83 RLU AMD RLU z
55 56 57 58 59 60 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4
R5 X4 R5:X4 R5 X4 R5:X4 no Drug RLU 12.05 152.18 16.55 116.57 L83
RLU 43 38 37 35 30 AMD RLU z 67 68 69 70 71 72 R5 X4 R5:X4 R5 X4
R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 no Drug RLU
77 50.04 411 34 12.09 7.857 41 191.63 38 669.39 17,443 45 387.62
16,707 38 439.66 L83 RLU 42 40 164 AMD RLU z 79 80 81 82 83 84 R5
X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4
R5:X4 no Drug RLU 6.92 0.41 1.23 11.05 223.03 4,107 33 124.45 L83
RLU 42 AMD RLU z 91 92 93 94 95 96 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4
R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 no Drug RLU 0.03 0.00 42
40 L83 RLU AMD RLU z drug: active RLU Intiut 100 tropisin ratio
limit : CxCke : drug: AMC 1 2 3 4 5 6 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4
R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 no Drug RLU L83 RLU AMD
RLU z 13 14 15 16 17 18 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4
R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 no Drug RLU L83 RLU AMD RLU z 25 26
27 28 29 30 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4
R5:X4 R5 X4 R5:X4 no Drug RLU 997.12 L83 RLU AMD RLU z 37 38 39 40
41 42 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4
R5 X4 R5:X4 no Drug RLU L83 RLU AMD RLU z 49 50 51 52 53 54 R5 X4
R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4
no Drug RLU 0.02 1033.01 3370.10 L83 RLU AMD RLU z 61 62 63 64 65
66 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5
X4 R5:X4 no Drug RLU 94.23 16.36 16.19 120.67 L83 RLU AMD RLU z 73
74 75 76 77 78 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5
X4 R5:X4 R5 X4 R5:X4 no Drug RLU 15.04 156.84 L83 RLU AMD RLU z 85
86 87 88 89 90 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5
X4 R5:X4 R5 X4 R5:X4 no Drug RLU 15.45 16.59 14.88 0.08 0.00 L83
RLU AMD RLU z 7 8 9 10 11 12 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5
X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 no Drug RLU 0.02 0.04 602.94 0.04
458.63 0.00 L83 RLU AMD RLU z R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4
R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 no Drug RLU L83 RLU AMD RLU z
19 20 21 22 23 24 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4
R5 X4 R5:X4 R5 X4 R5:X4 no Drug RLU 0.02 217.29 63.65 0.66 322.30
L83 RLU AMD RLU z 31 32 33 34 35 36 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4
R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 no Drug RLU 0.05 5.53
749.67 13.66 13.42 L83 RLU AMD RLU z 43 44 45 46 47 48 R5 X4 R5:X4
R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 no Drug
RLU 0.13 15.87 612.72 67.63 269.17 716.97 L83 RLU AMD RLU z 55 56
57 58 59 60 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4
R5:X4 R5 X4 R5:X4 no Drug RLU 12.05 152.18 16.55 116.57 L83 RLU 43
38 37 35 30 AMD RLU z 67 68 69 70 71 72 R5 X4 R5:X4 R5 X4 R5:X4 R5
X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 no Drug RLU 77 50.04
411 34 12.09 7,857 41 191.63 38 669.39 17,443 45 387.62 16,707 38
439.66 L83 RLU 42 40 164 AMD RLU z 79 80 81 82 83 84 R5 X4 R5:X4 R5
X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 no Drug
RLU 6.92 0.41 1.23 11.05 223.03 4,107 33 124.45 L83 RLU 42 AMD RLU
z 91 92 93 94 95 96 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4
R5 X4 R5:X4 R5 X4 R5:X4 no Drug RLU 0.03 0.00 42 40 L83 RLU AMD RLU
z active RLU Intiut 100 tropisin ratio limit: CxCke z R5 X4 R5:X4
R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 no Drug
RLU L83 RLU AMD RLU % inhib by L83 % inhib by AMD z 14 R5 X4 R5:X4
R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 no Drug
RLU L83 RLU AMD RLU % inhib by L83 % inhib by AMD z 25 26 R5 X4
R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4
no Drug RLU L83 RLU AMD RLU % inhib by L83 40 % inhib by AMD z R5
X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4
R5:X4 no Drug RLU L83 RLU AMD RLU % inhib by L83 % inhib by AMD z
49 50 53 54 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4
R5:X4 R5 X4 R5:X4 no Drug RLU 38 83 L83 RLU 3,502 13,880 AMD RLU 88
16,980 6,220 % inhib by L83 % inhib by AMD 7 z 62 63 64 65 R5 X4
R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4
no Drug RLU 4 L83 RLU 34 AMD RLU 2,773 797 % inhib by L83 % inhib
by AMD 6 73 74 75 76 77 78 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5
X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 no Drug RLU 391 15.04 98 38 4,449
L83 RLU 56 AMD RLU 340 % inhib by L83 87 % inhib by AMD 15 z 85 86
87 88 89 90 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4
R5:X4 R5 X4 R5:X4 no Drug RLU 510 33 979 59 16.55 491 6.08 297 5.06
L83 RLU 42 59 49 AMD RLU 564 376 % inhib by L83 92 94 90 4 % inhib
by AMD 111 14 z 7 8 9 10 11 12 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4
R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 no Drug RLU 0.02 49 0.04 42,206
0.04 44,589 L83 RLU 104 AMD RLU 37 % inhib by L83 % inhib by AMD z
19 20 21 22 23 24 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4
R5 X4 R5:X4 R5 X4 R5:X4 no Drug RLU 100 11,299 212.29 1,273 0.66
4,397 16,119 L83 RLU 3,058 22 26 1,455 49 3,874 AMD RLU 8,232 1,129
2,283 1,656 1,285 % inhib by L83 109 98 41 % inhib by AMD z 31 32
33 34 35 36 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4
R5:X4 R5 X4 R5:X4 no Drug RLU 0.05 177 32 5.53 24,739 13.60 2,997
0.31 416 L83 RLU 32 31 AMD RLU % inhib by L83 % inhib by AMD z 43
44 45 46 47 48 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5
X4 R5:X4 R5 X4 R5:X4 no Drug RLU 45 0.13 714 45 15.87 11,029 L83
RLU 207 31 18 73 59 AMD RLU % inhib by L83 % inhib by AMD z R5 X4
R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4
no Drug RLU L83 RLU AMD RLU % inhib by L83 % inhib by AMD 55 56 57
58 59 60 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4
R5:X4 R5 X4 R5:X4 no Drug RLU 0.39 470 L83 RLU 43 9,150 38 8,290 37
31 AMD RLU 41 784 38 316 3,038 % inhib by L83 99 59 % inhib by AMD
3 7 67 68 69 70 71 72 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4
R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 no Drug RLU L83 RLU AMD RLU % inhib
by L83 % inhib by AMD z 79 80 81 82 83 84 R5 X4 R5:X4 R5 X4 R5:X4
R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 no Drug RLU 263 38
3,890 L83 RLU 33 44 6,140 33 1,244 30 AMD RLU 1,109 % inhib by L83
87 99 % inhib by AMD 48 71 z 91 92 93 94 95 96 R5 X4 R5:X4 R5 X4
R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 R5 X4 R5:X4 no Drug RLU
L83 RLU 33 12,051 85,018 AMD RLU 451 51 45 % inhib by L83 34 %
inhib by AMD 100 R5 No Drug No Drug 34 14,140 46 21,555 30 3,909 39
49 42,205 45 44,580 32 26,471 55 6,849 38,144 2,336 31 1,211 1,120
1,140 20,119 4,552 149 47,389 611 46 281 100 11,299 1,213 7,375
16,115 19,102 226 72 1,130 5,204 52 67,828 14,582 3,288 50 668 231
51 177 24,739 612 2997 416 68 12,020 4,384 37 242 35 924 32 31 100
3,724 450 148 32 60 45 714 11,029 2,908 13,957 24,377 39 2,310 668
24 22 61 339 45 19 44 35 83 18,257 5,413 9,254 5,219 470 19,175 513
3,264 107 4,209 8,151 39 40 29 23,816 3,759 786 340 4,318 3,851 411
2,857 25,437 17,443 16,707 40 48 21 43 37 51 77 34 11 45 98 4,449
4,357 5,060 1,886 261 3,800 2,689 475 4,107 26 38 28 105 3,635 309
257 413 34 45 43 46 59 33 3615 z L83 L83 30 54 29 27 32 34 37 60 35
60 40 19,258 32 4,606 25,512 28 811 311 28 40 99 30 21 38 32 22 26
40 42 68 9,056 153 38 14,085 2,918 1,58 33 129 111 59 38 32 47 28
12 31 48 22 28 43 10,839 3,397 60 221 43 29 38 37 33 30 30 32 31 18
31 73 59 39 2,656 463 35 28 65 35 31 115 13,805 85 35 30 43 38 37
96 35 30 68 3,102 6,220 34 33 34 9,150 29 39 31 34 28 23 39 22 42
35 40 104 24 38 28 28 27 11 50 31 43 34 73 38 33 44 33 30 30 28 35
45 49 77 2,002 59 6,110 42 55 49 29 32 25 31 35 33 36 20 27 27 42
55 1,661 z AMD AMD 39 12,186 32 2,236 36 3,661 34 40 33,192 44
30,510 35 32 29 40 39 408 41 42,295 26 45 25 11,990 34 24 51,146
8,580 2,049 51 434 219 26 361 21,767 479 935 597 39 3,184 539 49 39
153 1,984 206 139 33 43 39 366 2,306 12,139 16,045 28 72 30 26 36
38 37 16,989 27,832 5,943 48,152 2,219 284 310 19,638 600 3,038 31
88 8,111 35 43 2,773 797 282 5,366 3,161 184 2,108 263 4,595 11,719
13,708 12,485 41 22 49 39 14 140 47 3,252 906 4,473 111 1,105 159
6,862 2,571 31 31 39 35 51 27 813 326 368 25 35 41 29 31 69 55 35
30 z
[0316]
8 Plate Repeat End time Start temp. End temp. BarCode 1 1 6:39:36
PM 21.6 21.7 NA 0.5 CPS (CPS) 18 26648 54 6970 37406 7158 38 1386
930 100 1184 19248 262 72 18972 3478 3946 5010 46 14 11004 106 9038
4002 32 238 26 976 34 38 48 38 2000 528 16 16 36 298 52 14 54 122
2984 7264 40 38 20 23344 15340 44 156 36 52 28 40 28 40 62 32 38 22
22 32 28 9858 68 3802 46 11470 1958 42 30 64 36 3846 3390 57858
12620 126186 68 34 ate Repeat End time Start temp. End temp.
BarCode 2 1 6:41:51 PM 21.5 21.6 N/A CPS (CPS) 34 26294 56 6728
38882 7514 24 1048 1326 40 1134 18956 190 72 20458 4418 4714 5398
58 26 10708 30 15002 4766 42 246 44 972 30 28 42 40 2620 808 32 28
86 378 38 22 32 92 5434 9638 36 42 38 24348 25446 34 96 44 44 14 46
46 62 92 36 44 54 30 44 28 8346 142 3468 30 7684 1438 44 36 54 30
3784 3840 65330 14284 130290 56 32 Plate Repeat End time Start
temp. End temp. BarCode 3 1 6:44:06 PM 21.6 21.6 N/A 0.5 CPS (CPS)
16 18590 18 4306 23902 5386 30 924 894 32 660 8698 148 34 14088
2880 3142 3160 40 46 7616 30 10252 3542 38 172 34 842 30 32 44 28
2396 370 28 26 66 172 32 22 28 64 3784 4822 32 28 24 6188 5702 34
120 16 28 62 26 28 30 38 38 38 44 38 52 40 7020 68 1798 62 7324
1076 50 32 50 70 3824 3138 53670 13088 104608 32 38 Plate Repeat
End time Start temp. End temp. BarCode 4 1 6:46:20 PM 21.7 21.8 N/A
0.5 CPS (CPS) 24 19926 46 5086 27182 5550 26 704 974 32 862 11214
158 42 15882 3026 2694 2956 26 20 5294 56 11426 3252 82 270 52 814
36 40 64 32 2916 556 42 30 64 242 38 24 36 72 3220 7618 36 38 44
12112 10878 32 246 32 48 22 30 28 22 136 30 56 34 32 38 40 8844 86
2386 54 4956 1372 50 22 34 40 3498 2754 59808 11014 65428 34 40
Plate Repeat End time Start temp. End temp. BarCode 5 1 6:48:35 PM
21.9 21.9 N A 0.5 CPS (CPS) 38 38 28 40 30 38 234 46 30 46 30 26 20
32 976 190 58 46 24 28 2298 42 3260 420 50 36 34 102 26 34 24 28
378 88 32 34 32 40 42 54 26 36 62 11690 38 44 32 42 42 26 36 46 22
44 38 58 32 38 30 32 36 22 38 52 40 42 26 34 50 200 36 36 80 52 40
36 40 52 54 22 40 te Repeat End time Start temp. End temp. BarCode
6 1 6:50:50 PM 21.8 21.9 N/A CPS (CPS) 30 26 28 40 34 40 50 38 44
34 36 42 28 32 1068 114 38 22 46 30 2268 36 3508 656 48 40 34 88 30
34 56 28 166 56 28 18 40 18 38 32 34 32 114 5732 32 42 34 38 34 50
34 36 22 36 40 30 20 30 26 42 40 46 24 26 32 60 28 32 40 120 36 32
58 58 32 24 40 50 36 12 38 112 30488 7474 60 9736 32 52 38 40 32 44
28 42 24 38 36 82 27748 6786 40 9654 30 52 30 22 24 46 48 34 42 46
34 48 23382 2842 32 7616 34 36 26 34 24 62 34 42 32 50 32 44 21176
4906 44 6906 32 42 40 32 42 24 24 46 28 24 18 34 22 1290 26 40 24
30 48 46 42 38 12 34 36 42 36 40 40 1280 40 30 36 26 32 38 52 26 36
20 36 40 18
[0317]
9 Plate Repeat End time Start temp. End temp. BarCode 1 1 ########
21.7 21.6 N A 0.5 CPS (CPS) 32 24 14218 56 21586 28 4034 36 52
42088 40 4780 174 71276 730 48 326 28 12022 1288 7198 69452 15306
4008 44 792 180 50 182 25292 718 72 3922 546 128 44 66 30 900 11984
3194 30 88 18820 40438 4852 105946 8466 4934 470 20386 3420 934 344
6268 5012 170 3546 504 8164 22214 344 82 5344 5330 6710 1880 338
4286 2112 466 580 1018 516 318 302 40 414 32 20 52 te Repeat End
time Start temp. End temp. BarCode 2 1 ######## 21.9 21.9 N/A CPS
(CPS) 22 44 14062 36 21726 32 3942 24 46 42324 50 4324 124 63502
492 44 242 172 10576 1258 7552 66204 14658 3568 56 524 282 56 172
24186 506 128 3526 354 168 20 54 60 528 10074 2622 40 78 17378
38076 5944 89520 10042 5564 470 17964 4118 638 336 4110 3624 222
4160 318 7550 28660 438 114 3554 3384 5470 1892 188 3494 2066 484
440 940 466 282 292 38 472 36 24 38 Plate Repeat End time Start
temp. End temp. BarCode 3 1 ######## 21.9 22 N/A 0.5 CPS (CPS) 36
36 38 28 28 38 28 36 42 114 40 32 34 80 26 16 36 30 18 26 30 126
106 34 42 30 46 22 26 32 58 26 46 42 38 34 20 18 34 24 36 28 146
15756 76 32 26 42 52 36 106 34 50 20 24 32 18 38 18 36 38 38 38 28
36 80 50 38 44 34 38 40 30 38 30 24 22 38 36 34 36 Plate Repeat End
time Start temp. End temp. BarCode 4 1 ######## 21.9 22.7 N/A 0.5
CPS (CPS) 16 24 70 30 26 26 40 18 32 66 30 24 46 118 34 26 40 34 26
26 50 132 116 84 34 34 48 34 38 30 38 32 30 32 28 26 40 46 28 12 26
34 84 12036 94 38 34 44 24 38 86 24 28 42 44 24 28 40 26 48 32 62
24 58 32 66 26 28 44 32 22 44 80 60 28 40 28 28 34 32 30 Plate
Repeat End time Start temp. End temp. BarCode 5 1 ######## 22 22
N/A 0.5 CPS (CPS) 34 38 11132 26 6696 34 3960 44 40 29548 40 762 48
39888 88 40 30 36 8416 1262 4096 52058 8050 2524 60 450 168 32 340
22410 534 106 2080 172 170 38 38 30 444 7478 2458 30 46 16428 25792
4240 45094 2092 630 334 17130 2498 732 358 5044 3236 202 2124 292
4806 13736 290 30 3986 886 4584 240 110 940 1286 162 456 816 438
294 260 44 524 40 34 22 ate Repeat End time Start temp. End temp.
BarCode 6 1 ######## 22 22.1 N/A CPS (CPS) 32 40 13240 38 7756 38
3368 24 40 36836 48 914 34 44702 64 50 20 24 8048 996 3826 50234
9110 1574 46 536 270 20 382 21124 424 200 1888 240 108 28 46 30 288
9302 2154 46 28 17532 29872 5846 51810 2346 938 286 22146 3048 862
206 5668 3686 166 2092 214 4384 15762 390 64 3518 926 4362 318 176
1032 924 156 672 810 314 242 252 26 378 30 20 34 43332 38 4314
17856 3572 424 16106 23794 548 3376 15146 19592 7752 4078 48 42
45846 26 4480 14374 2422 408 11888 24960 478 3152 19740 13822 9198
4136 38 50 60 46 48 80 8 28 100 60 34 24 50 58 30 28 22 26 60 34 36
56 36 28 46 58 36 36 30 150 30 28 18 28 30628 34 1598 12372 1046
512 10024 15470 388 2730 13012 12386 6768 2204 38 20 30392 36 1714
11588 804 682 14254 16620 612 3346 14404 12586 6956 2938 50 38
[0318]
10 R5 cells X4 cells R5:X4 R5 X4 R5:X4 no drug 34 26,471 0 no drug
67,389 72 936 R5 inhibitor 19,258 R5 inhibitor 99 X4 inhibitor 32
X4 inhibitor 42.295 % inhib by R5 inhibitor 27 % inhib by R5
inhibitor 100 % inhib by X4 inhibitor 100 % inhib by X4 inhibitor
37 0.00 257.09 0.01 0.57 0.00 129.65 0.02 0.04 602.94 0.04 459.68
0.00 0.24 0.66 935.96 0.03 0.01 0.07 0.02 217.29 63.65 0.08 0.82
322.30 CXCR4 997.47 1.29 0.86 2.72 6.60 0.05 5.53 749.67 13.60 0.31
13.42 CCR5 1.61 0.67 6.17 0.13 15.87 612.72 67.63 269.17 716.97
DUAL or MIXED 0.33 0.02 2.14 1033.08 135.33 3370.10 0.38 0.26 12.05
152.18 16.55 116.57 DEAD 94.23 16.38 16.19 120.67 116.70 3.84 50.04
12.09 191.63 669.39 387.62 439.66 15.04 158.89 0.46 58.00 6.92 1.23
11.05 223.03 124.45 15.45 16.59 14.88 0.08 0.08 0.00 0.03 0.00 z T6
95 R5 X4 R5:X4 R5 X4 R5:X4 no drug 14,982 12,020 1 no drug R5
inhibitor 111 10,839 R5 inhibitor X4 inhibitor 8,580 3,384 X4
inhibitor % inhib by R5 inhibitor 99 10 % inhib by R5 inhibitor %
inhib by X4 inhibitor 100 % inhib by X4 inhibitor z
[0319]
Sequence CWU 1
1
16 1 26 DNA Artificial Sequence Description of Artificial Sequence
RT Primers for HIV envelope 1 ggagcattta caagcagcaa cacagc 26 2 21
DNA Artificial Sequence Description of Artificial Sequence RT
Primers for HIV envelope 2 ttccagtcav acctcaggta c 21 3 19 DNA
Artificial Sequence Description of Artificial Sequence RT Primers
for HIV envelope 3 agaccaatga cttayaagg 19 4 35 DNA Artificial
Sequence Description of Artificial Sequence PCR primer 4 gggctcgaga
ccggtcagtg gcaatgagag tgaag 35 5 37 DNA Artificial Sequence
Description of Artificial Sequence PCR primer 5 gggctcgaga
ccggtgagca gaagacagtg gcaatga 37 6 36 DNA Artificial Sequence
Description of Artificial Sequence PCR primer 6 gggctcgaga
ccggtgagca gaagacagtg gcaatg 36 7 35 DNA Artificial Sequence
Description of Artificial Sequence PCR primer 7 gggtctagaa
cgcgttgcca cccatcttat agcaa 35 8 38 DNA Artificial Sequence
Description of Artificial Sequence PCR primer 8 gggtctagaa
cgcgtccact tgccacccat bttatagc 38 9 34 DNA Artificial Sequence
Description of Artificial Sequence PCR primer 9 gggtctagaa
cgcgtccact tgccacccat btta 34 10 38 DNA Artificial Sequence
Description of Artificial Sequence PCR primer 10 gatggtctaa
gacgctgttc aatatccctg cctaactc 38 11 10 PRT Artificial Sequence
Description of Artificial Sequence Viral Entry Inhibitor Resistance
Mutation 11 Gln Leu Leu Ser Gly Ile Val Gln Gln Gln 1 5 10 12 10
PRT Homo sapiens 12 Gln Leu Leu Ser Ser Ile Met Gln Gln Gln 1 5 10
13 10 PRT Artificial Sequence Description of Artificial Sequence
Viral Entry Inhibitor Resistance Mutation 13 Gln Leu Leu Ser Xaa
Ile Xaa Gln Gln Gln 1 5 10 14 10 PRT Artificial Sequence
Description of Artificial Sequence Viral Entry Inhibitor Resistance
Mutation 14 Gln Leu Leu Ser Asp Ile Val Gln Gln Gln 1 5 10 15 10
PRT Artificial Sequence Description of Artificial Sequence Viral
Entry Inhibitor Resistance Mutation 15 Gln Leu Leu Ser Xaa Ile Val
Gln Gln Gln 1 5 10 16 36 PRT Artificial Sequence Description of
Artificial Sequence Fusion Inhibitor Peptide 16 Tyr Thr Ser Leu Ile
His Ser Leu Ile Glu Glu Ser Gln Asn Gln Gln 1 5 10 15 Glu Lys Asn
Glu Gln Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu 20 25 30 Trp
Asn Trp Phe 35
* * * * *
References